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ABSTRACT
Human papillomaviruses (HPV) are etiologic agents of many epithelial tumors in
humans. The broad spectrum of HPV-induced pathologies ranges from common warts to
neoplastic lesions of the cervix uteri. Numerous recent studies reported the presence of
HPV sequences in precancerous and malignant skin tumors. A particularly high
prevalence of HPV DNA could be demonstrated in skin tumors of immunosuppressed
transplant recipients. Surprisingly, a substantial proportion ofl{PV types involved tumed
out to belong to the larger group of I{PV types originally believed to be exclusively
associated with tumors in patients with epidermodyspiasia verruciformis (EV). 0f total
81 of cutaneous samples were collected from renal transplant recipients (RTR), skin
squamous ceil carcinoma (SCC), actinic keratosis (AK) and participants without skin
lesion. Samples were analyzed using two published primer pairs (FAP59/64 and
I{VP2fB5) to detect HPV DNA in cutaneous samples. We were able to detect HPV DNA
in 91% (68/75) from RTR, SCC, AK and participants without skin lesion. Direct
sequencing and sequencing of cloned amplicons were performed and compared. By
comparing FAP59/64 versus HVP2/B5 primer pairs we were able to detect HPV DNA in
100% (8/8) of RTR with FAP59/64 versus 13% (1/8) with HVP21B5, in 38% (7/8)
versus 25% (2/8) of participants with 5CC, in 100% (8/8) versus 17% (2/12) of
participants with AK and in 87% (41/47) versus 9% (4/47) of participants without skin
lesion. Three novel types were described (LIOl, L102, L103). Multiples types were
found in 75% (6/8) of RTR samples, 83% (10/12) of AK samples, 71% (5/7) of 5CC
samples, 50% (6/11) of samples from normal participants older than 50 years, 50%
(15/30) of samples from normal participants younger than 50 years old.
Keywords: IIPV, SCC, RTR, AK, PCR
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RÉSUMÉ
Les papillomaviruse humains (HPV) sont les agents étiologiques du cancer du col de
l’utérus. Le spectre des pathologies induites par HPV s’ étend des verrues communes aux
lésions néoplasiques du col de l’utérus. Des études récentes ont rapporté la présence de
séquences de NPV dans les lésion précancéreuses et malignes de la peau. Un taux élevé
de détection d’ ADN de HPV est démontré dans les tumeurs de la peau de patients ayant
recu une greffe de rein. Etonnamment, une proportion substantielle des types de HPV
impliqués est révéléé appartenir au plus grand groupe de types de HPV associés aux
tumeurs des patients avec epidermodysplasia verruciformis (EV). 81 échantillons
cutanés recueillis chez des patients receveurs d’une greffe rénale (RTR), avec carcinome
squameu de la peau (8CC), de kératose actinique (AK) et sans lésion de la peau, ont été
analysé par PCR avec les amorces dégénérés FAP59/64 et HVP21B5. Ces paires
d’amorces ont été utilisée pour détecter I’ ADN de HPV dans de échantillons cutanés.
Nous pouvions détecter de l’ADN de HPV dans 91% (68/75) des spécimens. Le typage
par séquençage direct, après clonage des amplicons a été exécuté et les resultats
comparés. En comparant fAP59/64 et HVP2/B5, nous pouvions détecter de l’ADN de
HPV pour 100% (8/8) des patients avec RTR avec FAP59/64 contre 13% (1/8) avec
HVP2/B5, pouf 88% (7/8) contre 25% (2/8) des participants avec $CC, pour 100% ($18)
contre 17% (2/12) des participants avec AK et pour 87% (41/47) contre 9% (4/47) des
participants sans lésion de la peau. Trois types originaux ont été décrit (LIOl, L102,
L103). Plusieurs types de HPV ont été trouvé dans 75% (6/8) des échantillons de RTR,
83% (10/12) des échantillons de AK, 71% (5/7) des échantillons de 8CC, 50% (6/11) des
échantillons des participants normaux âgés de 50 ans et plus, 50% (15/30) des
échantillons des participants normaux plus jeunes que 50 ans.
Les mots clés : HPV, SCC, RTR, AK, PCR.
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LITERATURE REVIEW
2Introduction
Human papillomavimses (HPV) are small double-stranded DNA vimses found in
a wide variety of proliferative lesions of epithelial origin. In recent years there has been a
considerable increase in the number of identffied human papillomavims types. There are
currently more than 100 distinct types based on DNA sequence homology, but several
groups and partially characterized novel sequences have now been described, predicting
the existence of many more. Accumulating epidemiological and experimental data
strongly support that there is a relation between HPV infection and benign or malignant
neoplasia. Mthough the nature ofthe association is flot definitive, certain cutaneous HPV
types are found in a high percentage of non-melanoma skin cancers (NMSC) but no HPV
types have been associated specifically with NMSC in the general population. Some
cutaneous HPV types (I{PV-1, 2, 4, 7, 57) are associated with benign planter/palmer and
common skin warts [1]. On the other hand, evidence suggesting an etiologic role for HPV
in NMSC comes from studies on the rare disorder “epidermodyspiasia verruciformis”
(EV). About 30% of patients with this disease deveÏop squamous celi carcinomas (SCC)
ofthe skin, especially on sun-exposed sites [2].
In recent years, several consensus primer-mediated PCR techniques that allow for
the detection of a wide range of HPV genotypes have been designed. Many of these
methods have been used for detection ofIIPV types in healthy skin as well as in NMSC.
These methods have included single round PCR using one pair ofdegenerate primers [3],
combinations ofdegenerate primers [4,5,61 or nested PCRs using two pairs of degenerate
primers [7]. In our study we compared two primer pairs (FAP59/64 and HVP2/B5)
optimized to detect cutaneous HPV infection [3,4,8,9,10,111.
31 ITUMAN PAPILLOMAVIRUS:
1.1 History
Human papillomaviruses (HPV) are small, non-enveloped double-stranded DNA
epitheliotropic viruses [1]. They belong to the papillomaviridae family, members of
which infect squamous epithelia and cause proliferative diseases (papilloma) in a number
of vertebrates, including man, non-human primates, caille, rabbits and dogs, in a highly
species-specific manner.
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Figure (1): Human papillomavirus
HPV was the first tumor virus to be transmitted experimentally from one host to
another. This was accomplished in 1894 by Licht [2] who transmitted warts ftom his
brother to himself by inoculation of crude wart material. Ciuffo [3] in 1907 and Serra [41
one year later demonstrated that warts could be induced by celi- free filtrates of wart
material. In 1919, Wile and Kingrey [5] successfully transmitted warts through a
succession of human volunteers using sterile extracts of wart material, Electron
4microscopic studies by Strauss et al [6J, Melnick et al [7], Bunting [8] and Mmeirta et al
[9] confirmed a viral etiology for cutaneous warts.
Melinck in 1962 classified the papillomaviruses together with the polyomavimses
and 5V40 (Simian Vacuolating Virus 40) in the papovaviridae family because they were
small DNA vii-uses sharing ultra-structural features [10]. Reports of transmission of
fihrates ofwarts, laryngeal papillomas, and genital tract condylomas to human volunteers
who developed typical cutaneous warts at the sites of inoculation were interpreted as
indicating that there was one type of human wart virus and that the site of infection and
perhaps, the genetic makeup of the patient, determined the clinical appearance of
cutaneous warts and mucosal papillomas [11]. However, recognition that there were
different papillomavirus types ami subtypes stimulated a new interest in the i-ole of these
vii-uses in hyperpiasia and neoplasia arising in squamous epithelia of the anogenital and
digestive tracts [12,13,14,15,161.
12 HPVStructure andBiotogy:
1.2.1 General biology offlPV
HPV virons are non-enveloped icosahedral capsids (50 to 55 nm in diameter) of
72 capsomeres [17]. They do flot contain lipids and are inactivated by treatment with
0.4% formalin for 72 hours at 4°C [18]. Both complete and empty particles may be found
in tissue samples [19,20].
Molecular analysis of PV DNA was first determined by Crawford [21] and
Crawford [19,20]. Using stringent hybridization techniques without the aid of various
restriction endonucleases, it was concluded that although PV from various species had
similar structures and molecular weights, there was no polynucleotide sequence shared
among the different genomes analyzed. The PV genome is found in virions and infects
cells in three forms: a covalently closed, supercoiled molecule with a sedimentation
coefficient of 23 S, uncoiled circulai- molecule with a sedimentation coefficient of 17 S,
5and a linear molecule with a sedimentation coefficient of 16 S. [22,23]. The molecular
size ofthe genome based on agarose gel electrophoresis and contour length measurement
of DNA molecules by electron microscopy reveals a molecular weight of approximately
5x106 Daltons, corresponding to 8000 base pairs, which is sufficient to code for proteins
of 300,000 Daltons [12,131.
1.2.2 Mokecular biology of papillomavirus oncogenes:
Papillomavirus genomes for each type contain 9-10 open reading frames. With
variable spiicing pattems, they have the potential to synthesize 12-15 gene products. The
open reading frames labeled “E,” for early, represent those genes in bovine
papillomavirus (BPV) which were thought to be involved in episomal replication in
cultured ceils. The late, or “L,” genes encode the viral capsid proteins. The number afier
E or L refers to the size of the peptide coded by the open reading frame, one being given
to the largest peptide [24].
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figure (2): Simplified organization ofthe linearised genome of human papillomavirus type
16. The scale bar is in kilobase pairs. The rectangles represent the positions ofvarious open
reading frames (ORFs). The E genes encode proteins that are produced early in the
infectious cycle (the non-structural proteins), whereas the L genes encode proteins that are
produced late in infection (virion proteins that are necessary for virus assembly). The actual
protein products of the genes are complex owing to the production of multiple messenger
RNA (mRNA) transcrÏpts.
6Table (I): HPV gene products and their function.
Gene Function
El Initiation ofDNA replication
E2 Transcriptional regulationmNA replication
E3 ?
E4 Disrupts cytoskeleton?
E5 Transforming protein, interacts with growth factor receptors
E6 Transforming protein, binds to p53, leading to degradation of
p53
E7 Transforming protein, binds to pRB
E8 ?
LI Major capsid protein
L2 Minor capsid protein
1.2.2.1 The E6 oncoprotein:
Papillomavirus E6 protein consists of about 150 amino acids believed to bind a
zinc atom through two sets of cysteine repeats (cysteine X-X cysteine zinc fingers, where
X is any amino acid) [25,26]. The human papillomavims E6 proteins have moderate
homology at the amino acid level, indicating that while they share functions, they may
also differ. HPV-16 E6 has a haif-life of 30-60 min and is present in transformed and
cancer-derived celi unes at extremely low levels [27]. Several reports have demonstrated
that high and low-risk E6 genes can stimulate transcription equally, suggesting that some
E6 fiinction may be relevant to viral replication rather than correlate with oncogenic
potential [28,29,30].
7The high-risk HPV-16 and 12 F6 proteins interact with p53, as do $V 40 large T
antigen and adenovirus Elb [31]. HPV and other vimses presumably interfere with the
ability of p53 to block celi division and DNA synthesis so that viral DNA can replicate to
high levels. Indeed these mutations could permit genetic drift that can circumvent
immune defenses. SV40 and adenovirus prevent p53 mediated ceil cycle arrest by
synthesizing large amounts of large T and Eib, which effectively hold p53 in inactive
complexes. F6 protein eliminates p53 functions tbrough a novel mechanism. It lias been
shown that formation of the F6-p53 complex in vitro induced p53 degradation through an
ubiquitin-dependent mechanism [32]. High-risk F6 binds a 100-kDa protein, called F6-
AP (for F6 Associated pfotein), which appears to be required for the binding of E6 to
p53, and is necessary for degradation of p53 [33]. The gene for E6-AP is a member ofthe
ubiquitin pathway for protein degradation [34]. It lias been reported that although low
risk (HPV-6 and 11) E6 also binds p53 with reduced efficiency, it is flot capable of
inducing p53 degradation [35].
Despite these important findings, there are several unes of evidence that suggest
that F6 possesses other ffinctions. BPV F6 does flot bind p53, yet fiuly transforms murine
C127 cells [36]. BPV F6 and HPV6 F6, which do not induce p53 degradation in vitro or
in vivo, can immortalize human mammary epithelial celis, although they are much less
efficient than HPV-16 [37]. HPV-$, which is found in cutaneous $CC in patients
suffering from epidermosysplasia verruciformis, does not bind or degrade p53 in vitro
but, similarly to BPV F6, transforms mouse cells [32,39].
1.2.2.2 The f7 Oncoprotein:
The F7 oncoprotein is an acidic 98 amino acid phosphoprotein that has been
localized in the nuclear matrix [40]. Two cysteine-X-X-cysteine motifs in the carboxy
terminus of the protein mediate zinc binding and dimerization [41]. The recognition of
the amino acid similarities between the ITPV F7 protein and the DNA tumor virus
transforming proteins SV4O Large T and adenovims Fia facilitated elucidation of the
biochemical properties of F7 [42,43]. These regions of similarity were shown to bind the
8tumor suppressor gene product Rb and the reiated p107 proteins [44,45,46,47]. Both Rb
and p107 regulate ceil cycle division but act at different steps. The p107 binding region
ofE7 overlaps with but can be distinguished from the Rb binding domain [48,49].
It is though that when E7 binds Rb or p107, a transcription factor nonnally bound
to Rb/p107 is released, because E7 and the factor bind the same pocket [50,51]. This
factor, called E2F, is a sequence-specific DNA binding protein, and the DNA motif it
recognizes is found in many genes essential for celi division [52]. There is evidence that
the events induced by the Rb/ p107 association with F7 can lead to a complex yet
coordïnated cascade of positive and negative signais that allow a celi to replicate its DNA
and divide. Other regions of F7 bind additional growth-related cellular factors. HPV-16
F7 has been identifled in complexes with histone kinase, p33 and cydliui A and casein
kinase II, which phosophorylation may in part relate to the oncogenic potential of high
riskE7 [53,54,55,56].
Both HPV-16 and 18 F7 induced focus formation in murine ceil une
transformation assays [57,5$]. Consistent with its interaction with RbIp 107, addition of
F7 alone into primary human keratinocytes resulted in an increased rate of proliferation
for an extended period oftime, although celis eventually senesced [59]. Using very high
efficiency retroviral-mediated infection of primai-y human keratinocyes, it has been
shown that low-risk HPV-6 F7 can cooperate with high-risk E6 to induce immortalization
of primary human keratinocyes, and in the alternative mixing experiment, HPV-6 F6
cooperated with HPV-16 F7 to induce immortalization, although in both instances, the
efficiency was less than with high-risk E6 and E7 [60]. As with E6, there remain
unidentified properties ofE7 that are required for its transforming activities. For example,
mutations in F7 that do not affect Rb/p107 association interfered with its ability to
transform and immortalize ceils [61].
9figure (3): E7 Effects on Rb. E7 binding to Rb Ïeads to the release of
sequestered E2f, enabling the ceil cycle to progress
1.2.2.3 The E5 oncoprotein:
The F5 protein represents another fascinating and ingenious means developed by
papillomaviruses to prime cells for viral replication. An F5 gene has been identified in
bovine, deer, elk, and some human papillomaviruses. These animal viruses cause dermal
fibroblast proliferation (fibropapillomas) along with an epithelial component in their
hosts. E5 protein is small: the BPV E5 gene product contains only 44 amino acids. The
I{PV E5 gene is ofien deleted or its gene flot expressed in human cervical carcinomas,
whereas E6 and F7 are always transcribed. This suggests that F5 plays a mie at an early
stage of viral carcinogenesis. BPV-1 and HPV-6c ES have been reported to transform
established murine fibroblast ceil unes, whereas HPV-L6 ES did flot [36,62,631.
10
Introduction of HPV-16 E5 into established murine keratinocyte unes induced their
tumorigencity in nude mice, suggesting a potential role in human malignancy [64].
In contrast to the HPVs, the major transforming protein of bovine papillomavirus
type 1 (BPVI) is the F5 protein, a 44-amino-acid highly hydrophobic protein that
localizes predominantly to the Golgi and exists as homodimers [65,66,67]. The BPV1 E5
protein is able to transform both murine fibroblasts and keratinocytes in transformation
assays in vitro [64,68]. The BPV1 F5 protein is able to bind to and activate the platelet
derived growth factor f3 receptor in the absence of exogenous ligand [69,70], and this has
been shown to correlate with cellular transformation [71]. BPV1 E5 also binds to the 16-
kDa pore-forming membrane component of the vacuolar proton ATPase (v-ATPase), a
protein essential for the acidification of intraceliular compartments such as lysosomes,
endosomes, and the Golgi [72]. The binding ofBPV1 E5 to the 16-kDa protein is able to
cause aikalization of the Golgi, and this has been shown to correlate with cellular
transfonnation [73]. Because of the structural similarities between the BPV1 E5 and
HPV-16 E5 proteins, and because BPV-1 F5 has strong transforming potential, work was
begun to determine if HPV- 16 ES was also an oncogene.
E5 seems to be important early in the course of infection. It stïmulates ccli growth
by forming a complex with the epidermal growth-factor receptor, the platelet-derived
growth-factor-B receptor and the colony-stimuiating factor-1 receptor [74]. Recently, F5
has also been shown to prevent apoptosis following DNA damage [75]. However, as
HPV-infected lesions progress to cervical cancer, the episomal viral DNA ftequently
becomes integrated into host-cell DNA. And a substantial part ofthe genome, commoniy
including the ES coding sequence, is deleted [76]. So, ES is flot obligatory in late events
of HPV-mediated carcinogenesis.
Unlike E6 and E7, the major viral oncoproteins, the E5 pfotein of HPV-16 is flot
commonly found in cervical carcinoma celis [77,78]. However, it is considered an
oncogene given its ability to transform mouse fibroblasts and keratinocytes, cause
mitogenic stimulation of human keratinocytes, and cooperate with E7 to stimulate
11
proliferation of human keratinocytes [64,79,80,81,82]. The E5 gene of HPV-16 is a 83-
amino-acid hydrophobic membrane protein [$3,841 that localizes to the Golgi apparatus,
endoplasmic reticulum, and nuclear membrane [85].
Multiple studies have suggested that the HPV-1 6 E5 gene could interact with
epidermal growth factor receptor (EGFR) signaling. Studies indicate that HPV-16 ES
causes an increased activation of the EGFR in the presence of ligand [79,80,81], and
coimmunoprecipitation experiments indicate that BPV-16 E5 can form a complex with
growth factor receptors [74]. The HPV-16 E5 protein also binds to the 16-kDa membrane
component of the v-ATPase [$5] and delays endosomal acidification in human
keratinocytes [86]. It has been argued that in binding with the 16-kDa protein, E5 disrupts
the 16-kDa protein-v-ATPase complex [87,8$], which resuits in the inhibition of
endosomal acidification.
E5 acts during the productive stage ofthe HPV-16 life cycle. A study showed that
HPV- 16 E5 mutants infecting basal celis resuits in a lower percentage of supra-parabasal
ceils undergoing DNA synthesis compared with ceils harboring the (Wild Type) WT
HPV-16 genomes [91]. Previously, it had been reported that E7 plays a critical role in the
productive stage of the HPV- 16 life cycle [89]. In that study, it was demonstrated that
HPV-16 E7 mutants do not reprogram supra-parabasal ceils to support DNA synthesis,
and this defect correlates with the absence of viral DNA amplification. That study also
established that ceils harboring HPV-16 F7 mutants failed to modulate the differentiation
program ofrafi cultures ofNIKS celis and displayed reduced expression ofLi, the major
viral capsid protein expressed in the productive stage of the HPV- 16 life cycle. In
contrast, the HPV-16 E5 mutant genomes did modulate the differentiation program in rafi
cultures ofMKS ceils, as was seen in NIKS harboring the WT HPV-16 genome. HPV-16
E5 mutants also expressed late viral proteins in the productive stage of the HPV- 16 life
cycle at the same levels as seen with HPV-16 WT. HPV-16 infected ceils retained viral
DNA amplification as analyzed by fISH. Thus, E5 plays a more subtie role during the
productive stage ofthe viral life cycle than does F7.
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A parallel study of E5 in the context of the HPV-3 I life cycle by Fehrmann et al.
[90] has also shown a subtle effect of F5 during the productive stage of the viral life
cycle. In both studies, the disruption of ES had no observable effect on the non-
productive stage of the viral life cycle. Specifically, HPV-16 and IIPV-3 1 with E5
mutations [90,911 could be maintained as nuclear plasmids. The E5 variation in HPV-16
was a deletion of an adenosine at position 30 of the F5 sequence. Celis harboring these
E5 mutant genomes displayed similar growth kinetics in the absence or presence ofEGF
in monolayer cultures compared to cells harboring the WT HPV genome. In contrast,
both studies noted defects during the productive stage ofthe viral life cycle.
Cells harboring HPV-16 E5 mutants displayed a significant reduction in the
percent of supra-basal cells undergoing DNA synthesis in raft culture. They also found a
lower induction of cyclins A and B and lower retention of proliferative potential in ceils
harboring HPV-3 1 E5 mutants, compared to those harboring WT genomes, upon
suspension of those cdl populations in semi-solid medium. In both studies, celis
harboring F5 mutants retained the ability to amplify viral DNA upon induction of cellular
differentiation. The investigators discerned a two-fold decrease in the degree of
amplification in celis harboring E5 mutants compared to those harboring WI’ HPV-3 1 by
Southem analysis. They also observed a twofold decrease in the ftequency of celis
supporting amplification of the E5 mutant genome, based on FISH analysis of
organotypic rafi cultures. However, this difference was flot statistically significant.
Southem analysis of DNA extracted from HPV-16 WT and HPV-16 ES mutant rafis
cultures was performed as described by Ozbun and Meyers [92] but they could flot detect
viral DNA amplification in the HPV-16 WT rafts or in rafts generated with a clone of
cervical epithelial cells (W12E cells) that harbored episomal HPV-16 DNA. They
believed that this absence ofdetectable amplification was due to the very low percentage
of celis (0.09 to 3.48%) within a rafi supporting viral DNA amplification as shown by
their fISH analysis [91].
Studies have indicated that HPV-16 E5 is able to cooperate with E7 to induce
proliferation, enhance immortalization, and promote anchorage-independent growth of
13
baby rat kidney ceils [79,93]. In these studies, it was found that transfection of F5 alone
into primary rodent ceils had littie effect on proliferation of these ceils and that F7 alone
was able to increase proliferation in comparison to the vector alone. However,
cotransfection of ES and F7 resulted in a significant increase in the amount of
proliferating colonies over that of F7 alone. Considering that F5 contributes to the
capacity of HPV-16 to reprogram differentiating celis to support DNA synthesis, a
property also reliant on E7 [89,91], F5 could play a cooperative role with F7 in the
productive stage ofthe viral life cycle [91].
The mechanism by which HPV-16 F5 is contributing to the productive stage of
the viral life cycle is not yet clear. Many studies have suggested a link between HPV- 16
ES protein and the EGFR signaling pathway. These studies suggest that when treated
with EGF, E5-expressing ceils display anchorage-independent growth [$1], increased
mitogenic potential [62,82], and increased growth factor receptor signaling (with or
without FGF) [67,94]. Whereas Laimins et al found littie, if any, EGFR present in
keratinocytes following suspension in semi-solid medium, other investigators clearly
found that FGFR was present in the superficial layers of rail cultures of early-passage
human foreskin keratinocytes or NIK$, albeit at lower levels than those observed in the
basal layers [91,95]. A similar expression pattem ofthe EGFR in basal as well as supra-
basal compartments of rail cultures has been reported in the context of an HPV-3 1-
positive CIN 1 lesion-derived population, the CIN 612 9F ceils [96]. In that study, the
authors also monitored expression ofHPV-3 1 F5 in the context of rail cultures and found
that E5 protein levels were induced in a time-dependent manner, suggesting that its
expression is tied to the differentiation and stratification of epithelial ceils. Consistent
with this observation, they detected F5-positive celis within the more superficiai layers of
the CN 612 9F rail cultures. These data indicate that both E5 and one of its known
targets, EGFR, are expressed within the terminally differentiating ccli compartment in
which we have observed an effect of F5 during the productive stage of the viral life
cycle.
The binding of HPV-16 F5 to the 16-kDa component of the v-ATPase may also
be important in F5’s contribution during the productive stage ofthe viral life cycle [85]. It
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has been shown that endosomal acidification ofHPV-16 E5-expressing celis is inhibited
and that this can lead to increased receptor recycling to the celi surface [86]. Another
study has suggested that HPV-16 E5 affects trafficking from endocytic compartment
rather than endosomal acidification [97]. Studies under way will allow us to determine
which ofthese mechanisms are involved in E5!s contribution during the productive stage
of the viral life cycle.
1.2.2.3.1 Interaction ofES with cettutarfactors:
BPV-1 F5 forms complexes with different transmembrane proteins. Thus, E5
directly binds to the transmembrane domain to the platelet-derived growth receptor B
(PDGFR) and ffinctionally interacts with the epidermal growth factor receptor (EGFR)
and the colony-stimulating factor-1 receptor (CSF-1R), [69,98,99]. Through these
interactions, the receptors may be activated in a ligand-independent manner. Moreover,
their signais, e.g. increased receptor phosphoiylation, mitogen activated protein kinase
activity and phospholipase C-y-1 activity are enhanced even in the absence of a
physiological ligand [67,100]. This may resuit from interference with receptor
degradation and intemalisation [101,1021.
NPV-16 and HPV- 6 E5 also have been shown to co-operate with the EGFR and
PDGFR [$0,8 1,82]. Moreover, HPV-16 E5 enhances endothelin receptor signaling [103].
Whereas HPV-6 F5 also associates with the EGFR, the related erbB2 receptor and the
PDGFR, HPV-16 E5 does flot bind to cellular growth factor receptors [104]. Another
common target of both BPV and HPV E5 proteins is a 16 kDa membrane pore protein
representing a subunit of the ff-dependent vacuolar ATPase [72,85]. For ATPase
binding, the glutamine residue within the hydrophobic domain seems to play an
important role [105]. As a result of this interaction, acidification of endosomes is
inhibited. This has been suggested to be responsible for the prolonged retention and
reduced degradation of the EGFR in the presence of the F5 protein [$6]. However, the
binding ofNPV-16 E5 to the 16 kDa ATPase subunit couid be dissociated from the F5-
mediated EGFR overactivation [1061.
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1.3 CtassWcation ofHPV:
Until the late 1 970s, papillomaviruses affracted littie interest as they were only
known as the causal agents of “warts”, benign cutaneous lesions in some mammals and
humans. Since warts are normally only a cosmetic problem but flot a major threat to
public health, they were mostly of academic interest. In the 1 980s, newly developed
powerful molecular biology techniques led to the detection of dozens of human
papillomaviruses in benign and malignant mucosal lesions [14,107], such as cervical
cancer and its precursor lesions, as well as in genital and laryngeal warts. Present data
support the existence of more than 100 HPV types. The whole genomes of about 100
HPV types have been isolated and completely sequenced, while we have only indirect
evidence for the other types, most ofien through the sequence of polymerase chain
reaction (PCR) amplicons, which unambiguously identified the presence of HPV-related
sequences. Description ofHPV types has changed several times in parallel with technical
progresses and phylogenetic analysis. An HPV type is now defmed as an isolate whose
Li gene sequence is at least 10% dissimilar to that ofany other known HPV types.
1.3.1 C]assification according to sequences nucleotides:
In the mid-1950s to 1960s, papillomaviruses and polyomaviruses were analyzed
by electron microscopy and basic nucleic acid analyses. These two groups of viruses
were found to be the only one with double stranded circular DNA genomes, and non
enveloped particles consisting of icosahedral capsids. As a consequence, they were
considered closely related and were placed ïnto a common family, the papovaviruses
Papoviridae. Sequence and functional studies in the 1 9$Os showed that these similarities
were too superficial to establish relationship [10$]. Ml polyomaviruses have a genome
size around 5 kb, while the genome of papillomaviruses is close to $ kb. Polyomaviruses
transcribe mRNA from both strands, while papillomavirus transcription occurs only in
one direction. And lastly, and most importantly, polyomavimses and papillomaviruses
do flot share any substantial amount of nucleotide or amino acid sequence similarity, with
the exception ofa small homologous segment in the T-antigen and Fi genes, respectively
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[109]. Since taxonomic classification should reflect natural relationships, it was
concluded that these vimses form two separate families. Only fairly recently, the famiiy
“papillomaviruses” (Papillomaviridae) became officially recognized by the International
Council on Taxonomy ofViruses (ICTV) [1101.
1.3.1.1 Papillomavirus types:
Papillomaviruses are identified by the abbreviation PV and one or two letters
indicating the host species. This can be derived from an English word, for example
“HPV’ for human papillomavirnses ami “CRPV” for coffontail rabbit papillomaviruses,
or the scientific name of the host, e.g. MnPV for Mastomys natalensis papiliomavims,
which infects an African rat. HPV types are identified by numbers considering the
historie sequence of their description, e.g. HPV- 1, HPV-2, etc. [111]. Presently, and for
the last 20 years, E.M. de Villiers at the Reference Center for Papiilomaviruses at the
German Cancer Research Center in Heidelberg has controlled this process [112]. New
HPV types have to be registered by this center to confirm completeness of the genomic
isolate. New types have to show 10% nucleotide sequence diversity in the Li gene from
ail known HPV types. Thereafier, assignment of a new number and publication of this
new HPV types is possible. HPV types, whose genome was generated by PCR rater than
traditional cloning techniques, are identified by addition of the abbreviation “cand” (for
candidate) before their number, e.g. candHPV-86 [110].
1.3.1.2 Subtypes:
The term “subtypes” was used in the 1980s to identifS? isolates of an HPV type
with different restriction nuclease digestion patterns. Subsequently, this term became
redefined as referring to an isolate whose Li sequence is 2-10% different from that of
any known type. A consequence ofthis redefinition was that several subtypes (e.g. HPV
6a, HPV-6b and HPV-6c) had to be eliminated, as they showed less than 2% sequence
diversity. $urprisingly, today only three HPV isolates are known to fulfihi this latter
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subtype definition. HPV-46, HPV-55, and HPV-64 had been originally described as
separate types, but their types status has now been cancelled, as they are subtypes of
HPV-20, HPV-44, and HPV-34, respectively [110].
1.3.1.3 Variants:
“Variants” ofHPV types differ by at most 2% in the ORF sequences or by at most
5% in the LCR of the original isolate characterized, also referred as “prototype” or
“reference genome”. Variants are identffied by PCR-sequencing mainly. This strategy has
been applied to numerous HPV types from isolates throughout the world
[113,114,115,116,117,118J. The two principal observations from these studies are that
there is apparently only a limited number (for example 20-100) of common variants for
each ITPV type, and that variants showed maximal divergence when they were sampled
from different groups living in different countries. HPV types have these coevoived with
the human species [1191. HPVs did not infect humans from an animal reservoir such as
for some other vimses, like Ebola, the SARS coronavirus, or influenza. There are
indications that variants of the same HPV type differ biologically and etiologically
[120,121]. Such differences may contribute to the disparities in the incidence of cervical
cancer throughout the world, although this question stiil requires substantial research
before conclusions can be drawn [122].
1.3.2 Classification according the site of infections (Genital, cutaneous or
mucosal):
It was found that different HPV types associated with similar lesions are
sometimes only very distantly related to one another. For example, HPV-1, HPV-2, HPV
4 and HPV-41 are ail found in wart-iike cutaneous lesions, but are on remote branches of
evolutionary trees. HPV-16 and HPV-18, the two HPV types that have become
paradigms in the research on cervical carcinogenesis, are less related to one another than
to some HPV types that are neyer found in cervical malignancies.
1$
Table (2): Cutaneous types ofHPV
ffPV Type
1, 2, 4, 26, 27, 29, 41, 57, 65
1, 2, 4, 63
3, 10, 27, 28, 38, 41, 49
1, 2, 3, 4, 7, 10, 2$
2, 27, 57
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2, 3, 10, 12, 15, 19, 36, 46, 47, 50
5, 8, 9, 10, 14, 17, 20, 21, 22, 23, 24,
25, 37, 3$
37, 38
Non-genital Cutaneous Disease
Common warts (verrucae vulgaris)
Plantar warts (myrmecias)
flat warts (verrucae plana)
Butcher’s warts (common warts of people who
handie meat, poultry, and fish)
Mosaic warts
Ungual squamous cell carcinoma
Epidermodyspiasia verruciformis (benign)
Epidermodysplasia verruciformis (malignant or
benign)
Non-warty skin lesions
Table (3): Mucosal types ofHPV (non-genital).
HPV Type
6, 11
6, 11, 16, 1$
6, 11,30
16,18
57
16,1$
6,11
16
13,32
16,18
16,12
16,18
Non-genital Mucosal Disease
Respiratory papillomatosis
Squamous cdl carcinoma ofthe lung
Laryngeal papilloma
Laryngeal carcinoma
Maxillary sinus papilloma
Squamous ccli carcinoma ofthe sinuses
Conjunctival papiliomas
Conjunctival carcinoma
Oral focal epithelial hyperplasia (Heck disease)
Oral carcinoma
Oral leukoplakia
Squamous ccli carcinoma ofthe esophagus
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Table (4): Mucosal types ofHPV (Anogenital).
HPV Type Ano-genital Disease
6, 11, 30, 42, 43, 44, 45, 54 Condylomata acuminate
16, 18, 34, 39, 42, 45 Bowenoid Papulosis
16, 18, 31, 34 Bowen disease
6,11 Giant condylomata (Buschke-Lôwenstein tumors)
30, 34, 39, 40, 53, 57, 59, 61, 62, Unspecified intraepithelial neoplasia
64, 66, 67, 6$, 69
6, 11, 43 Low-grade intraepïthelial neoplasia
31, 33, 35, 42, 44, 45, 51, 5216, 18, High-grade intraepithelial neoplasia
56, 58, 59, 66
6, 11, 16, 18 Carcinoma ofvulva Malignant Vulvar Lesions
16 Carcinoma ofvagina
16, 18, 31, 33, 35, 45, 51, 52, 56, Carcinomaofcervix
58, 59, 66
16, 18, 31, 33, 35, 45, 51, 52, 56, Carcinomaofanus
58, 59, 66
16 Carcinoma in situ of penis (erythroplasia of Queyrat)
16,18 Carcinoma ofpenis
1.3.3 Classification according to the high risk or Iow risk
As a consequence of infection and viral persistence in the epithelium, a variety of
proliferative lesions may arise in the skin or mucosa according to their preferential sites
of infection. These include benign warts and condylomas but also dyspiastic lesions,
which may ffirther de-differentiate and progress to cancer. Distinct clinical entities have
been found to be associated with distinct HPV types. Based on the biological or clinical
properties, HPV types have therefore been classified into “low-risk” types mainly
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associated with benign disease only and “high-risk” types also associated with malignant
disease (124).
In general, sometimes we are classifying types according to site of infection could led
to confiising contradictions. Examples ofthese contradictions include:
• HPV-6 and HPV-l I are typically found in genital warts or condylomata
acuminate in the genital tract, and they were therefore considered “genital” HPVs.
However, they are also found in non-genital sites, for example in papillomas of
the larynx [123].
• Genital warts can be of mucosal as well as cutaneous origin. HPV types involved
include mucosal types as well as HPV-2, HPV-27, and HPV-57, which are causes
ofcommon warts, and ITPV-7 [123].
1.4 Mechanism ofhuman papiiomavirus infection:
1.4.1 Entry:
Papillomavimses gain access to the basal celis through physical breaks in the
epithelial barrier. Basal ceils are infected by one or two copies ofthe episomal viral DNA
per celi. The extrachromosomal viral DNA in basal ceils replicates in concert with
normal cdl division thus maintaining a constant number of episomal HPV genome per
cdl. Presumably, the viral DNA is maintained in the daughter celis in upper levels ofthe
epithelium. It is in these strata of ceils undergoing differentiation that viral RNAs are
expressed at substantial levels [125]. The differentiation-specific cellular events promote
viral transcription and DNA replication. Thus papillomavirus is shed to high numbers
only in expendable, terminally differentiated ceils sloughed off the epithelium. NPV are
not lytic viruses [24].
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1.4.2 Shedding:
Aller many copies of the circular viral DNA are synthesized in the upper strata,
these genomes are incorporated into a particle, or capsid, which consists ofthe Li and L2
proteins. The viral capsid protects its DNA as the keratinocytes terminally differentiate as
well as after being shed into the envfronment. linportantly, papillomaviruses do flot bud
from the cell’s plasma membrane and thus do not incorporate a membrane-derived lipid
envelop. HPV particles are thus flot sensitive to environmental stresses such as heat,
soaps, or desiccation. Aller assembly, papillomaviruses are carried along with
differentiated ceils to the stratum corneum, where they are released with cell death due to
apoptosis [24].
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Figure (4): Schematic representation of a skin wart (papilloma). The papillomavims life
cycle is tied to epithelial cell differentiation. The terminal differentiation pathway of
epidermal ceils is shown on the lefi. Events in the virus life cycle are noted on the right.
Late events in viral replication (capsid protein synthesis and virion morphogenesis) occur
only in terminally differentiated celis.
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1.4.3 Coordination ofthe viral replication cycle:
After entering the appropriate host ccii, viral gene will be expressed in an ordered
fashion. Within the non-coding region (NCR) of each virus are DNA sequences that are
recognized by cellular transcription factors [126,127,128,129,130]. The papillomavirus
genotypes vary in the type, array, and position ofthese sites, which could have important
consequences for pathogenicity.
In addition to these binding sites for cellular factors, papillomaviruses encode a
DNA binding protein designated E2. E2 binds the inverted palindrome 5’-ACCG NNNN
CGGT-3’ with vely high affinity (—10’1M) [131], and multiple copies of this DNA
palindrome are found in every papillomavirus genome [132]. Their position ofien varies
among different genotype groups. E2 can stimulate, and under certain instances repress,
viral transcription [133,134,135]. E2 is also required for viral DNA replication. When F2
binds its recognition site, it usually stimulates transcription from the nearby promoters in
a classical “enhancer” mode.
The E2 protein averages about 400 amino acids with a monomeric molecular
weight of approximately 50 kilo-Daltons (KD) and has distinct functional domains
[136,137,138]. The carboxy terminal 100 amino acids of ail papillomavirus F2 proteins
constitute the DNA binding domain. This small region is sufficient for sequence-specific
DNA binding and dimerization, which E2 must do to bind DNA [139]. The atomic
structure of the BPV F2 protein bound to its cognate DNA site was found to fold as an
unusual B- barrel dimer with a DNA recognition helix crossing each monomer [140].
The amino terminal haif of the F2 protein is necessary for activation of gene
expression, so these amino acids must interface with the ccli’ s transcription machinery.
This region ofE2 represents its transcription activation domain. When F2 binds a specïfic
segment on the viral DNA through its DNA binding domain, its transcription activation
domain recruits the cellular factors that lead to synthesis of the viral mRNA. One such
23
factor may be Spi, although there is evidence that E2 activates transcription in concert
with a variety of basal promoter factors [141,1421.
The E2 DNA binding and transcription activation domains share considerable
homology among the papillomaviruses. Between these two regions is a variable stretch of
residues that are flot conserved, and are generally thought to represent a “flexible hinge.”
The E4 reading frame overlaps this E2 hinge region and the papillomaviruses differ
substantially in their E4 protein. E4 is flot essential for viral transcription, replication, or
transformation in vitro and is believed to serve a role in maturation of the viral capsid and
escape ofthe viral particle from the dense intermediate filament network of the epithelial
cell [143,1441.
Papillomaviruses do not express high levels of their RNAs and proteins until the
late stages of epithelial differentiation. To restrict expression of the viral genes, BPV and
HPV generates tmncated E2 proteins to act as transcriptional repressors
[145,146,147,148]. These repressors lack the amino terminal transcription activation
domain but retain a functional DNA binding domain [149]. Therefore they compete with
full-length F2 proteins for binding the E2 recognition sites on the viral genome. In
addition, the E2 protein normally is a dimer, and formation of a heterodimer between a
full-length and truncated F2 protein represents another mechanism for the inactivation of
E2-induced transcription [150]. Both full-length and tmncated E2 can repress viral
transcription factors to their recognition sites in the LCR Dominance of the latter
function may reduce viral expression in basal and parabasal kerationcytes.
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1.4.4 Reptication ofthe viral genome:
The viral DNA must be selectively replicated in differentiated celis to produce a
higli level of infectious progeny in each ce!!. This would normally be very detrimental
except that PV replication occurs in terminally differentiated cells. This highlights the
central paradox of papillomavirus replication: it begins in a non-replicating cdl layer in
which the multitude of enzymes necessary for DNA synthesis is thought flot to be
present. Because papi!!omavirus do flot encode a DNA polymerase or the associated
factors necessary to duplicate DNA, they must induce the ccli to replicate while
differentiating. Consequently, the virus must mobilize these ce!lular factors to repiicate
the viral genome.
Figure (5): The $000 base pair papillomavirus genome is shown diagrammatically
on the right. Vira! proteins are expressed in a highly organized paftern as an infected
cel! migrates towards the epithelial surface. The timing of viral protein expression in
infected epithe!ium is shown on the left.
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Papillomavims utilizes two proteins, E2 and El, to identify their genomes among
the mass of host DNA. Mutations in the viral El gene interfere with autonomous
replication ofthe viral DNA [151]. The El protein binds to E2 protein [152,153,154]. It
is believed that E2 and El each bring a set of cellular factors to the viral DNA, and these
factors replicate the viral DNA. E I wealdy binds a specific DNA sequence in the viral
regulatoiy region, and this activity of El is greatly enhanced when it is complexed with
E2 [155,156]. In BPV, the El binding site is adjacent to E2 sites, and this segment of
viral DNA is sufficient for autonomous replication in murine ceils when Fi and F2
proteins are expressed [157]. The El protein has helicase activity, which is necessary for
separating the HPV DNA strands prior to their replication [158]. Both BPV and HPV Fi
and F2 are necessary for viral DNA replication [159,160,161].
2 Human papïllomavirus and skin cancer:
2.1 Normal skin:
The skin is considered the largest organ of the body and has many different
functions. The skin functions in thermoregulation, protection, metabolic functions and
sensation. The skin is divided into two main regions, the epidermis, and the dermis, each
providing a distinct role in the overali function of the skin. The dermis is aftached to an
underlying hypodermis, also called subcutaneous connective tissue, which stores adipose
tissue and is recognized as the superficial fascia of gross anatomy.
The epidermis is the most superficial layer of the skin and provides the first
barrier of protection from the invasion of foreign substances into the body. The principal
celi of the epidermis is called a keratinocyte. The epidermis is subdivided into five layers
or strata. The outermost part of the epidermis is called the stratum comeum, or homy
layer. li is composed of dead keratinocytes (the main type of ceil of the epidermis) that
are continually shed. Below the stratum comeum are layers of living keratinocytes, also
called squamous ceils. These ceils form an important protein called keratin. Keratin
contributes to the skin’s ability to protect the rest ofthe body.
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The lowest part of the epidermis, the basal layer, is formed by basal ceils. These
celis continually divide to form new keratinocytes, which replace older keratinocytes that
wear off of the skin surface. The basement membrane separates the epidermis from the
deeper layers of skin. Melanocytes are also present in the epidermis. These skin cells
produce the protective brown pigment called melanin. Melanin makes the skin tan or
brown. It protects the deeper layers ofthe skin from the hannful effects ofthe sun.
The middle layer ofthe skin is called the dermis. The dermis is much thicker than
the epidermis. It contains hair follicles, sweat glands, blood vessels, and nerves that are
held in place by collagen. Collagen, which is made by skin fibroblasts, gives the skin its
resilience and strength.
Lymph vesse!
Figure (6): Section of skin showing epidermis and
dermis layers.
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The last and deepest layer of the skin is called the subcutis. The subcutis and the
lowest part ofthe dermis form a network of collagen and fat ceils. The subcutis conserves
heat and lias a shock-absorbing effect that helps protect the bodys organs from injury.
2.2 Types ofnonmetanoma skin cancer (NMSC):
Skin cancers are cÏassified into 2 general categories: nonmelanoma and
melanoma. Nonmelanoma skin cancers (NMSC) are the most common cancers of the
skin. Melanocytes can also form malignant melanoma and benign growths (moles). There
are many types of NMSCs, but 2 types are most common--basal cefl carcinoma and
squamous cell carcinoma.
Figure (7): Squamous Ceil Carcinoma
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Squamous ccli carcinomas deveiop in higher levels of the epidermis and account
for about 20% of ail skin cancers. They commonly appear on sun-exposed areas of the
body such as the face, ear, neck, hp, and back ofthe hands. They can also develop within
scars or skin ulcers elsewhere. Less ofien, they develop in the genital area. SCCs tend to
be more aggressive than basal ceil cancers. They are more likely to invade tissues
beneath the skin, and slightiy more likely to spread to lymph nodes andlor distant parts of
the body.
Basal ceii carcinoma begins in the iowest layer of the epidermis, called the basai
ccii layer. About 75% of ail skin cancers are basal ccli carcinomas. They usuaily develop
on sun-exposed areas, especially the head and neck. Basal cdl carcinoma was once found
almost exclusively in middle-aged or older people. Now it is also being seen in younger
people, probably because they are spending more time in the sun with their skin exposed.
Basal celi carcinoma is slow growing. It is highly unusual for a basal ccli cancer to
spread to lymph noUes or to distant parts of the body. However, if a basal ccli cancer is
lefi untreated, it can grow into nearby areas and invade the bone or other tissues beneath
the skin. Affer treatment, basal ccli carcinoma can recur in the same place on the skin.
Mso, new basai ccli cancers can start elsewhere on the skin. Thirty-five to fifty percent of
people diagnosed with one basai ccli cancer develop a new skin cancer within 5 years of
the first diagnosis.
Less common types of NM$C include: Kaposi’s sarcoma, cutaneous lymphoma,
skin adnexal tumors, various types of sarcomas, and Merkel ccli carcinoma. Together,
these types account for less than 1% ofNMSCs.
2.3 Precancerous andpreinvasive skin conditions:
2.3.1 Actinic keratosis:
Actinic keratosis (AK) is thickened, scaly (keratotic) growth of the skin, also
known as solar keratosis. Actinic keratosis arc small, rough spots that may be pink-red or
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flesh-coiored. Usuaily they deveiop on the face, ears, back of the hands, and arms of
middle-aged or older people with fair skin, although they can arise on other sun-exposed
areas ofthe skin. Individuais with one actinic keratosis usually develop many more.
Actinic keratosis represents atypical keratinocytic proliferations confined to the
epidermis. Histological changes of altered ccli polarity, variation in ceil size and
basophilicity, enlarged nuclei, prominent nucleoi, and mitosis are present in AK, ail of
which are aiso seen in SCC [162,163,164]. The difference between AK and SCC is
strictly architectural. AKs by definition are confïned to foci in the epidermis, whereas
SCC involves the full thickness of the epidermis with extension into adnexai epithelium
and the dermis.
80% ofAKs appear on sun-exposed skin ofthe head, neck, arms, and hands. They
are more common in whites (17 per 1,000) than blacks (0.2 per 1,000). The clinicai
course ofAK is unpredictable and ranges from spontaneous disappearance to progression
to SCC with potential for metastasis. Estimates of progression ftom AK to SCC over 10
years have varied from 13% to 20% [165,166J. Mthough AKs have traditionaliy been
described as premalignant, evidence now indicates that AKs and $CCs lie on a clinical,
histological, cytological, and molecular continuum [162,167,168,1691. Thus, AKs are flot
premalignant but are truiy malignant in that the cells comprising AK have alrcady
undergone neoplastic transformation, and the evolution from AK to SCC involving the
dermis and deeper structures represents progression rather than transformation [170].
2.3.2 Squamous celi carcinoma in situ:
Squamous ccli carcinoma in situ, also called Bowen’ s disease, is the earliest form
of squamous ccli skin cancer. The ceils of these cancers are contained entirely within the
epidermis and have not invaded the dermis. Bowen’s disease appears as reddish patches.
Compared with actinic keratosis, Bowen’s disease patches tend to be larger, redder, more
scaly, and crusted. Like invasive squamous ccli skin cancers, the major risk factor is
30
overexposure to the sun. Bowen’s disease of the anal and genital skin is ofien related to
sexually transmitted infection with HPVtypes-16, 18, 31) the types that can also cause
genital warts or preinvasive cervical disease.
3 Ultraviolet rays (UVR) and skin:
Most skin cancers are linked to sunburn or prolonged exposure to the sun. Skin celis
are damaged by the electromagnetic radiation that makes up sunshine. The dangerous
rays contain UV radiation and can penetrate deep into our ceils and cause gene damage,
the trigger for cancer. There are three types ofUV: UVA, UVB and UVC.
3.1 ([VA
UVA is the predominant type of UV radiation from the sun. It increases
production of melanin in the skin, resulting in a temporary tan. UVA doesn’t burn the
skin. UVA rays cause aging, wrinlding, and loss of elasticity. UVA also increases the
damaging effects of UVB, including skin cancer and cataracts. Long term exposure can
lead to skin cancer.
3.2 UVB
UVB radiation makes up a very small proportion of the sun’ s UV radiation. But it
can cause redness and burning. Prolonged exposure can resuit in blistering and second
degree burns. Exposure to UVB rays is a risk factor for both NMSCs and malignant
melanoma. UVB rays cause a much greater risk of skin cancer than UVA.
3.3 UVC
UVC radiation gets filtered out by the ozone layer and does flot reach the earth. It
can be artificially produced for example in arc welding lamps and is extremely damaging
to the skin.
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Figure (8): Effect ofthe sunlight on the
skin
3.4 Measurement of UVR:
In cutaneous photobiology, radiant exposure is ftequently expressed as ‘exposure
dose’ in units of J/cm2 (or 11m2) ‘Biologically effective dose’, derived from radiant
exposure weighted by an action spectmm, is expressed in units of 1/cm2 (effective) or as
multiples of ‘minimal erythema dos& (MED).
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3.5 UVR in humai, skin
Responding to a variety of stimuli resulting in DNA damage, the sequence-specific
transcriptional activator p53 is well known as a “guardian ofthe cell cycle” [124]. The
E6 proteins of the high-risk HPV types, HPV-16 and HPV-1$, bind to wild-type p53 in
vitro and target its degradation via the ubiquitin pathway. Mutant p53 proteins which do
flot complex with F6 are flot degraded [310], whereas those mutations leading to
conformational change of the p53 protein, are degraded [311]. The E6 proteins of the
low-risk genitai NPV types do bind top53, although degradation is flot induced [32,312].
p53 mutations are frequently present in actinic keratosis and malignant tumors (squamous
ccli carcinoma and basal celI carcinoma) ofthe skin. The majority ofthe mutations are C-
T or CC-TT transitions, with mutationai hot-spots occur-ring predominantly in the DNA
binding region of the p53 gene [188,313-3171. These mutations are mainly induced by
UVB exposure, although similar mutations have been demonstrated in malignant tumors
from PUVA-treated (psoralen and UVA) psoriasis patients [31$]. The mechanism by
which cutaneous HPV types interact with cellular proteins in the pathogenesis ofNMSC
la poorly understood. The transcriptional transactivation activity of p53 following DNA
damage by UV radiation is inhibited by the HPV-1$ E6 [319] as well as the HPV-1 F6,
but flot by the E6 ofthe cutaneous types, HPV-5, 8 and 47 [320] or HPV-77 [298].
On the other hand, little is known about the functional significance of the
mutations present in the p53 proteins in NMSC. The clonai expansion of p53-mutated
normai keratinocytes (as demonstrated by microdissection) indicates that the mutationai
event may be an early event [321,322]. An arginine substitution ofa praline at the codon
72 of the p53 gene, resuiting in electrophoretically distinct forms of the protein [323],
was recently shown to be significantiy more susceptible to high-risk HPV E6-mediated
degradation [211]. This polymorphism was demonstrated in a large number of actinic
keratosis samples [18$] and squamous ccli carcinomas ofthe skin [2111, but a functional
correlation with skin tumors remains to be determined. Codon 24$ is regarded as one of
the mutational hotspots in NMSC [314,316,317]. In vitro studies demonstrated that this
p53 mutant was unable to transactivate a reporter gene, to inhibit ccli proliferation or to
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interfere with c-jun activity even though no change in its conformation was noted [324].
The introduction of human p53 proteins with mutations at codons 175, 248 or 273 into
mouse ceils with no endogenous p53 genes induces a tumorigenic potential in these celis
and thus leading to a gain of fiinction. p53 mutant proteins also act as a trans-dominant
mutation influencing the oligmeric protein complexes with wild-type p53 proteins [325].
Wild-type p53 proteins are less stable with a haif-life of approximately 20 min compared
to several hours for the mutant p53 proteins. This resuits in a much higher level of mutant
p53 in tumor tissue, the presence ofwhich is demonstrated by specific antibodies [325].
Base substitutions in the tumour suppressor gene p53 found in human squamous
ceil skin carcinomas that had developed at sites exposed to the sun, were similar to those
found in experimental systems exposed to UVR, and especially to UVB.
I. UVA radiation is mutagenic to prokaiyotes and induces DNA damage in ffingi. It
is mutagenic to and induces DNA damage, chromosomal aberrations and sister
chromatid exchange in mammalian cells. It also induces DNA damage and mutation
in human celis in vitro [3281.
II. UVB radiation is mutagenic to prokaiyotes and induces chromosomal
aberrations in plants. It is mutagenic and induces DNA damage, sister chromatid
exchange and transformation in mammalian cells. It is also mutagenic and induces
DNA damage and transformation in human celis in vitro and induces DNA damage
in mammalian skin celis irradiated in vivo [328].
ifi. UVC radiation induces DNA damage and is mutagenic to prokaryotes, ffingi
and plants, induces DNA damage in insects and aneuploidy in yeast. It induces
sister chromatid exchange in amphibian and avian cells in vitro. It is mutagenic and
induces DNA damage, chromosomal aberrations, sister chromatid exchange and
transformation in mammalian and human cells in vitro. It also induces DNA
damage in mammalian skin cells irradiated in vivo [328].
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3.6 UVR and skin cancer:
NMSC is the most ftequently occurring malignancy worldwide in the Caucasian
population [171]. Resuits ftom epidemiological studies suggest that exposure to sunlight
increases the risk of NM$C. NMSC in a normal population occurs mainly on sun
exposed sites areas to UV radiation as a major environmental factor in the pathogenesis
of these tumors [172]. Differences in incidences of 50-fold for BCCs and 100-fold for
SCCs have been noticed among the white population in northem Europe and Australia.
The rates observed in the Hawain white population are substantially lower than those for
Australian whites, indicating that additional factors other than sun exposure may be
important for the induction of NMSC [173]. This idea is substantiated by observations
made in Finland where BCC could not be associated with outdoor occupations such as
farming, fishing and forestry [174], as well as in cases of BCC developing on less
exposed areas [175]. Solar UVB radiation represents one of the major environmental
impacts for humans [176] resulting in about 40,000 new cases ofNMSC arising annually
in the UK and 1,000,000 in the USA.
3.7 Other riskfactors ofnon-metanoma skin cancer (NMSC):
There are many etiological factors that has been proposed to cause NMSC,
chemical exposure (arsenic, tar, coal, paraffin), long-term or severe skin inflammation or
injury, immunodeficiency, human papillomavirus, psoriasis patients treated with psoralen
and ultraviolet light (PUVA), smoking, male gender, histoiy of previous skin cancer,
radiation therapy (such as radiation treatments for leukemia, goiters, ankylosing
spondylitis), Xerodenna pigmentosum (very rare inherited condition that reduces the
skin’s ability to repair damage to DNA caused by sun exposure) and Basal cell nevus
syndrome (rare congenital condition present at birth) and age.
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3.8 Psoriasis:
Psoriasis is a chronic relapsing, inflammatoiy papulosquamous dermatosis.
Psoriasis occurs worldwide affecting 2% of the population. Scalp involvement is a
prominent feature (50%). It may appear at any age, but the age of onset has bimodal
peaks in the teens and again in the sixties. The pathophysiology involves abnormal
hyperproliferation of the skin with a rapid celi turnover time in the epidermis (3-4 days).
This is probably secondary to activation of the cellular immune system producing a
variety of cytokines (especially IL-1), eicosonoids (especiaily LT B4) and polyamines.
The changes in epidermal ccli kinetics result in alterations in the epidermal cell keratin
cytofilament expression, and ceilular differentiation.
There are five different types of psoriasis. The most common form of psoriasis is
called “plaque psoriasis,” which is characterized by well-defined patches of red raised
skin. About 80 percent of people with psoriasis have this type of lesion. Plaque psoriasis
can appear on any skin surface, although the knees, elbows, scalp, trunk and nails are the
most common locations.
3.8.1 Psoriasis and UVR and ffPV:
Psoriasis can be viewed as a hyperproliferative disorder of keratinocytes mediated
by T celis. In contrast to lichenoid skin diseases, there is no microscopic evidence for the
presence of apoptotic keratinocytes in psoriasis, despite Fas expression. One possible
expianation is that Bcl-xL, shown to block apoptosis, is overexpressed in keratinocytes
within lesional plaques [1961. In this respect, increased epidermal thickness in psoriasis
can be explained by abnormaiities in the apoptotic ccli death pathway.
UVR has been used for several decades to treat skin diseases, notably psoriasis. A
variety of sources of TJVR are empioyed, and nearly ail emit a broad spectrnm of
radiation. A typical dose in a single course of UVB phototherapy might lie between 200
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and 300 times the MED. Psoralen ami UVA (PUVA) photochemotherapy has been
widely used in the treatment of inflammatory and malignant dermatoses for over 20
years. It is a highly effective and well tolerated treatment for many patients but its use is
limited by the associated risk of developing NMSCs [197,198,199,200,201]. The risk of
SCC in particular is increased up to 80-fold compared with the normal population. BCC
also occur at a higher than expected frequency in PUVA patients [202], although the
increased risk is considerably less than for SCC. The BCC: SCC ratio is then similar to
that seen in immunosuppressed fenal transplant recipients (RTR) [203].
Several factors are thought to determine the risk of skin cancer in PUVA patients,
including, in particular, cumulative UVA dose and numbered treatment [204]. Sun
sensitive skin type and past exposure to ionizing radiation, arsenic, and methotrexate may
also be important factors. Psoralens intercalate between complementaiy strands ofDNA,
particularly at A-T rich sites, with formation of mono- and bi- functional adducts
following photoactivation by UVA radiation [205]. PUVA has also been shown to induce
cutaneous and systemic immunosuppression that may be an additional important
determinant of its carcinogenic potential [205,206,207,208,209].
3.9 Epidermodysptasia verruWormis (EV»
Epidermodyspiasia verruciformis (EV) is a rare, lifelong, autosomal recessive
hereditary disorder affecting the skin. The disease usually begins in infancy or early
childhood (about 7.5%), during childhood (in chiidren aged 5-11 years) (61.5%), or at
puberty (22.5%) with the development ofvarious types ofwarts and plaques on the skin.
The lesions may progress to form verrucous plaques and nodules, or they may transform
into SCCs. The clinical course is protracted. As the disease progresses, some lesions
disappear, while new lesions may appear on other areas of the body. The rate of
appearance ofnew lesions varies considerably.
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Individuals with EV have a specific impaired cellular immunity to EV-associated
HPV types that increases their susceptibility to widespread viral infection. The disease is
characterized by chronic infection with HPV. Widespread skin eruptions of flat-to
papillomatous, wart-like lesions and reddish brown pigmented plaques on the trunk, the
hands, the upper and lower extremities, and the face are characteristic. The lesions may
transform into malignant carcinomas, usually afier age 30. Skin cancers initially appear
on sun-exposed areas, sucli as the face and the ear lobes. Patients with EV are usually
infected with multiple types ofIIPV. More than 30 HPV types, including types 3, 5a, 5b,
8-10, 12, 14, 15, 17, 19-21, 23-26, 37, 38, and 47, have been identified in EV tumors.
Ceils with early signs of malignant transformation have been found to be close of virus
infected epidermal regions. Mthough the exact mechanisms involved in the malignant
transformation of keratinocytes in skin lesions of patients with EV are unknown,
cooperation between HPV and UV is suspected.
Figure (9): Epidermodysplasia verruciformis. Emptive, polymorphic,
warty papules and plaques on the lower extremities of a patient with
epidermodysplasia verruciformis.
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The progression on sun-exposed sites ofbenign to malignant lesions requires a lag
phase of 20-30 years as was observed in skin autographs in these patients from non-sun
exposed and uninvolved skin [210]. Only benign lesions developed within the grafts,
whereas premalignant and malignant changes occurred around the grafis during the
subsequent observation over 20 years. These data suggest that additional factors are
involved in the process ofcutaneous carcinogenesis.
4 Cellular defense meclianisms against oncogenesis:
4.1 Apoptosis:
Apoptosis, or programmed ccli death, is the major mechanism by which
homeostasis of a number of physiological systems in the body can be reguiated.
Furthermore, recent studies have suggested that the failure of celis to undergo apoptotic
ccli death might be involved in the pathogenesis of a wide variety of human diseases,
including cancer, autoimmune disease, and viral infections [177]. There is accumulating
evidence that apoptosis occurs flot only in the pathologicai conditions of the skin, but is
an ubiquitous process that is important in regulating epidermai growth [178,179,1801.
In the skin, celis dying by apoptosis have been found in a wide variety of
conditions, such as inflammatoiy dermatoses and skin tumors [178,179,180]. Evidence is
accumulating that apoptosis plays an important role flot only in the pathogenesis of skin
diseases, but is also invoived in the homeostatic mechanisms in healthy skin. Apoptosis
triggers a series of events leading to the efficient elimination of a ccli. In actively
proliferating tissues, such as the epidermis of the skin, apoptosis-like phenomena are
oflen found, as seen in the regression of hair foiiicies [181,182] and in terminal
differentiation [183,184,185]. For exampie, “sunburn ceils”, ftequentiy observed in
epidermis treated with UVB, have the apoptotic characteristic of condensed nuclei
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[186,187], the response to UVB radiation being in part dependent upon the expression of
p53 [188]. This p53 -driven response, ofien termed cellular proofteading, eliminates rather
than repairs, severely damaged ceils. However p53-independent pathways have also been
described [189,190].
4.1.1 Bd-2 family
The Bel-2 is a proto-oncogene that was originally discovered as a resuit of its
location at the site of a transiocation between chromosomes 14 and 18. It is present in
most human follicular lymphomas [191]. Mthough initially viewed as an oncogene, Bd
2 has littie mitogenic effect. Instead, its oncogenic potential has been attributed to its
ability to inhibit apoptosis. Bd-2 prolongs the survival ofcells in the absence ofrequired
growth factors by blocking apoptosis, even in the presence of a variety of stimuli such as
chemotherapeutic agents, irradiation, TNF, heat shock. Furthermore, the introduction of
genes that inhibit Bd-2 can induce apoptosis in a wide variety oftumor ceil types, which
suggests that many tumors continually rely on Bel-2 to prevent celi death.
A number of Bel-2 family members have been identified. Bel-2, Bcl-xL, Bel-w
and Mcl-1 inhibit apoptosis, whereas others, such as Bax, Bik, Bak, Bad, and Bcl-xs
activate apoptosis.
4.1.2 Bak protein
Bak, the pro-apoptotic effectors, a member of the Bc12 family which activates
apoptosis, is expressed in human epidermal keratinocytes [192,193] and is a target ofthe
E6 protein of anogenital HPVs [194]. The impact of cutaneous HPV E6 proteins resulting
in Bak dysfiinction has important physiological implications with regard to skin cancer
development [195].
UV irradiation of skin leads to a marked increase in the level ofthe Bak protein, a
pro-apoptotic member of the Bc12 family. Using a combination of in vitro and in vivo
assays, the E6 proteins from phylogenetically diverse IIPV groups was shown to
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stimulate the degradation of Bak via the ubiquitin-mediated pathway, thereby inhibiting
apoptosis.
One study showed that both normal human keratinocytes and HT1O8O celis
treated with UVB had dramatically increased levels of the Bak protein brought about by
an increase in haif-life, pointing to a role for Bak in promoting apoptosis in UVB
damaged skin. In contrast, 1ff 1080 celis expressing the anogenital and cutaneous HPV
E6 proteins showed no such increase in Bak levels following UVB damage. Bak is the
first identified target of cutaneous E6 proteins. The mechanism of degradation, shared
with anogenital NPVs, indicates that the E6 proteins from cutaneous types are able to
discriminate between p53 andBak as targets [195].
The protelytic degradation of Bak protein by E6 promotes leads to a decrease in
apoptosis in UV-irradiated damaged ceils, which could in tum promote tumor formation
[195]. ITPV E6 proteins may have the potential to inhibit Bak-induced apoptosis in skin
following UVB damage, resulting in the accumulation of deleterious mutational changes,
which ffirther increase the genetic instability of NPV-containing lesions. Irradiation of
epidermis regenerated from HPV-transfected keratinocytes showed that ceils failed to
accumulate Bak and did not undergo apoptosis [195]. They concluded that Bak ffinction
was to removes precancerous celis from the epidermis resulting from UVB damage.
Evidence that HPV-positive NMSC lesions have undetectable levels of Bak protein,
together with resuits suggesting that anogenital and cutaneous HPVs may possess the
ability to use a common anti-apoptotic mechanism, raise the exciting possibility that the
abrogation ofBak by the HPV E6 proteins is a common means of promoting the survival
of infected ceils. This may provide a useffil target for intervention against skin lesions
harboring a wide variety of HPV types [195]. Preliminaiy screening of HPV-positive and
negative tumour biopsies revealed that the NPV-positive tumours consistently failed to
express the Bak protein, whilst HPV-negative tumours frequently retained Bak
expression. These findings point to a critical role of the Bak protein in eliminating UV
damaged skin celis and suggest that the inhibition of this pathway by the E6 protein
contributed towards malignant conversion.
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Figure (10): Apoptotic pathways in the skin and potential points of
abrogation by the HPV E6 protein.
Several possible mechanisms of how RPV might act as a cofactor in cutaneous
ceil transformation have been proposed. The promoter activity of HPV-77 is stimulated
by UV radiation and the response is mediated through a binding site for the p53 tumor
suppressor protein in the upper regulatoiy region of the virus [298]. Moreover,
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Ultraviolet-induced cytokines and interferons have been foùnd to activate the promoter of
the cuanteous HPV-20 [299]. The E6 proteins of cutaneous HPV types seem to harbour
relatively low oncogenic capability, showing transformation and anchorage-independent
growth of rodent celis, but without forming tumors in nude mice [39,300]. Recently,
primary human celis were reported to be transfonned by E6 ofHPV-38 [301]; however,
the E6 protein ofthe cutaneous HPV types appear to be unable to promote degradation of
p53 [38,195], in contrast to that of oncogenic genital NPV types [303].
The E6 protein of cutaneous human papillomavimses might promote genomic
instability of infected celis since it was demonstrated that E6 of HPV types 1 and $ (and
HPV type 16) binds to the XRCCI protein (required for the repair ofDNA single-strand
breads and genetic stability) [304]. Aslo, the E6 protein of cutaneous HPV-5, 10, and 77
binds the pro-apoptotic Bak protein [302]. This could inhibit Bak-induced apoptosis
following ultraviolet radiation that could resuit in accumulation of deleterious mutational
changes. Mutations are frequent in SCC of the skin and more than 90% of such lesions
demonstrate mutations in the tumor suppressor gene p53 [3051.
5 Prevalence of IIPV on the skin:
5.1 Prevatence ofHPV in RTR and Immunosuppressedpatients:
Renal transplantation is a well-established procedure, with many grafi recipients
surviving 20 years or more. However, a major problem associated with long-term
immunosuppression is the increased prevalence of various malignancies, especially in
skin, anogenital tract and lymphoreticular system [214,215,216,217,218,219]. Moreover,
renal allografi recipients (RARs) frequently develop a spectrum of cutaneous
complications ranging from benign viral warts (VWs), to verrucous and AK exhibiting
varying degrees of dysplasia, and SCC [220]. The prevalence and morbidity of such
complications increase with duration time of immunosupression. A longer duration of
immunosuppression for RARs increases the risk of developing multiple skin tumors
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[221]. In RARs, the ratio ofSCCs to BCCs is 15:1, a reversai ofthe 1:5 ratios normally
observed in immunocompetent patients. It is well recognized that NMSC occurs 10-20
years earlier in renal transplant recipients compared to immunocompetent individuals
[2031.
Renal transplant recipients given immunosuppressive therapy for long periods of
time have an increased incidence of cutaneous neoplasia [22 1,222,223]. Mso, more than
90% of kidney recipients develop skin warts and 40% develop skin cancer within 15
years of transplantation, a 50-to 100-fold increase compared to the general population
[224]. EV-associated HPV types have been found in skin tumors from such patients
[2,225,226,227,228]. A number of factors have been implicated in the deveiopment of
skin cancers in RARs. Ultraviolet (11V) radiation is known to be of considerable
importance as the majority oftumors occur on sun-exposed skin [216,229,230,231]. It is
well established that renal allografi recipients have an increased incidence of viral warts
and premalignant and malignant cutaneous lesions. The risk for these lesions increases
with the duration ofgraft survival. It has been postulated that, in addition to the effects of
prolonged immunosuppression and previous sun exposure, HPV may also contribute to
the carcinogenic process. Studies on HPV DNA detection on RTR has been somewhat
controversial, with EV-associated types and a variety of cutaneous and genital HPV types
being identified in some but flot all studies [162,221,232,233,234,235]. Studies on
samples from renal transplant recipients and immunosuppressed patients showed that the
prevalence ofHPV DNA ranged from 33% to 84.1% in SCC patients, 75% in BCC, 79%
in warts and 42%-$8.2% in actinie keratosis [212,223,236,237,238].
In one study [236], HPV DNA was detected in at least one of the samples from
94% (49/52) of the renal transplant recÏpients and from 82% (23/28) of the dialysis
patients. A histoiy of skin cancer (basal or squamous cdl carcinoma) was common in the
renal transplant recipient group (11.5%, 6/52), whereas no case of skin cancer had been
noted in the dialysis patients or healthy controls [236]. Five of the six renal transplant
recipients with a history of skin cancer were positive for HPV DNA. They used swab
samples collected from five different sites on the skin of renal transplant recipients,
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dialysis patients, and age- and sex-matched healthy controls. Most individuals were
found to have asymptomatic HPV infections as we mentiend above in addition to 80%
(64/80) of healthy controls were positive for HPV DNA [236]. There was a significant
difference between immunosuppressed renal transplant recipients and non
immunosuppressed patients under dialysis and healthy controls with regard to the
prevalence ofHPV DNA (p<O.O5) [236]. HPV types detected were 20 known types and
30 putatively new types [236]. IIPV DNA has also recently been detected in plucked
hairs from renal transplant recipients (92% positive) as well as from healthy volunteers
(53% positive) [237,2481.
5.2 Prevatence ofHPVDNÀ in immunocompetent individuats with skin
tesions:
In immunocompromised patients, warts and SCCs contain a diverse spectrum of
HPV types, the virus being present in 80% of lesions from immunocompromised
patients and 30% of lesions from Ïmmunocompetent patients [211,212]. The co
localization of warts and cancers at sun-exposed sites suggests a possible interaction
between HPV and UVB irradiation [21 3J. There were several notable differences between
lesions from immunocompetent compared with immunosuppressed patients. The overall
prevalence of HPV DNA in squamous celi carcinomas, basal ceil carcinomas and
carcinoma in situ was significantly lower in immunocompetent individuals than in renal
transplants immunosuppressed [2121. In immunocompetent patients, the prevalence of
HPV DNA is 13%-27% in SCC, 100% in warts, 25% in actinic keratosis, 31%-36% in
BCC, and 32%-33% in I’JMSC and about 13% in melanoma skin lesions
[212,223,236,23 7,23$],
5.3 Prevalence ofHPVDNA in heatthypeopte:
Human skin harbors a very large spectrum of HPV genotypes, most of them
previously unknown [2,225,237,238,239,240J. Moreover, there could be a ffirther
substantial number of skin papillomavirus types that remains to be detected. Studies show
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that the prevalence of HPV DNA ranges from 53%-80% of the healthy controls. for
example in one study [236], HPV DNA was detected in 80% of healthy controls. HPV
was detected more frequently on the forehead (76%) than on the arms (48%-49%) or
thighs (38%-44%) [236]. In that study, a simple sampling method in which a saline
soaked cofton-tipped swab was gently drawn over a small area of skin was utilized to
collect ceils for HPV detection. In another study, skin surface swab samples from one or
more sites on three of four healthy volunteers were found to contain HPV {241J.
In another study [237], HPV DNA was detected in plucked hairs from healthy
volunteers (53% positive) [248]. These hair samples were taken from different areas of
the body. In the resuits reported in this study, HPV DNA was not only detected in the
normal skin from the eyelids, but also in samples ftom other body sites (wrist, car,
forehead, temple, check, and leg) [237].
EV HPV types have been detected in hairs plucked from normal skin of 67% of
heakhy controls [242]. In another study [237], 35% of biopsy specimens from normal
skin obtained during cosmetic surgery was positive for HPV DNA. EV-HPV types are
frequently detected on the skin of healthy individuals, but also in skin cancer lesions of
RTRs [2,225,227,239,243]. Therefore, it seems warranted to stop calling them EV
associated HPVs. Preferably, they should be classified according to phylogenetic super-
groups [244], or, in a broader sense, simply referred to as cutaneous HPV types.
The presence of I{PV, and specifically some EV-HPV types, on the normal skin
supports that infection with a broad spectrum of HPV types occurs frequently [2,2371.
The natural histoiy of cutaneous HPV infection is unknown at present. Longitudinal
studies are needed to delineate persistence of as well as the natural histoiy of infection by
cutaneous HPV types. Genomes ofhuman papillomaviruses are common in biopsies from
NMSCs but are also found on healthy skin. It is thus possible that HPV positivity in
tumor biopsies by PCR may merely reflect contamination of the lesion by the skin. To
investigate tins issue, 229 immunocompetent patients were tested for HPV DNA in swab
samples collected over skin tumors and in biopsies of the same tumors, obtained after
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stripping with tape to remove superficial layers. HPV DNA was detected on the skin of
69% (159 /229) oflesions, and in 12% (28/229) of stripped biopsies. The difference was
seen for ail four types of tumours studied. Sebon-hiec keratosis had 79% (34/43) HPV
positivity on the skin versus 19% (8/43) in biopsies. Actinic keratosis had 83% (3 8/46)
HPV positivity on skin versus 11% (5/46) in biopsies. Basal celi carcinoma had 63%
(69/109) positivity on skin versus 8% (9/109) in biopsies and 5CC had 58% (18/31)
positivity on skin versus 19% (6/31) in biopsies. HPV DNA is coinmon in superficial
layers of lesions, but is not necessarily present throughout tumors [245J.
6 Detection assays for cutaneous ffPVprimers pairs:
Until recently, it has been technicalÏy difficuit to detect the 80 or more
characterized HPV types in skin cancer, considerably hindering research in this area. In
early studies, detection of HPV DNA in NM$C varied both in overail prevalence (from
0-64%) and in the spectrum of HPV types detected [213J. These discrepancies largely
reflected the performance of detection methods used. Direct DNA-hybridization based
techniques were generally employed using a limited number ofHPV probes that were not
informative for the majority of HPV types and were not sensitive. As a consequence, the
tme prevalence of HPV in cutaneous lesions was underestimated. Where polymerase
chain reaction (PCR) was employed, early methods used type-specific primers capable of
detecting only a limited range ofHPV types [223,246,247].
PCR with primers targeting consensus DNA sequences in the Li and El open
reading frames (ORF) have been successffihly used applied the detection of a wide range
ofgenital HPV types [249,250,251,252]. PCR with consensus primers specially designed
for cutaneous HPV types have also been developed [2,225,228,238,248,253]. However,
cunent methods for the detection ofcutaneous HPV types have disadvantages such as the
use of nested PCR. Nested PCR predisposes to obtaining false positive resuits due to
contamination. Other assays require combinations of several degenerate primers. The use
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of degenerate primers aflow for the amplification of several types in one reaction but
resuits in a lower sensitivity than type-specific PCR or PCR assays using pools of non
degenerate primers [2,225,253]. Moreover, use of the different PCR approaches lias
resulted in discrepant reports ofHPV DNA in skin lesions [254].
TaNe5: Secpmcea af011 paickc6deias apime
HPV dam HPVr detcctcd ORF Primer Sequence (5’-3’) Atniealing site Sizc(bp) Degtiuacy
HPVtype Bases
cuteoiis Genetal cutaneoua LI FAP59 TAACYGTIGGICAWCCYTATI’ 8 5981-6001 478 t
FAP64 CCYATATCYVHCATfltItCCATC 64584136 36
Cutas,eow GIct*aneota LI HVP2 TCNMGNGGNCANCCNTmGG 18 5934-5953 650 16,384
35 AYN1TRTTGNG 6361-6580 512
cigasiecus LI 1WP7 AYICCCRflRTTCATXCC\70
HVP9 AYXCCRTIRTJDCTGXCCYTG
Q4mrcus 1,41,63 Li CNIF AATARG11WGATGATGCWGAA 1 5793-5814 309-328 8
‘ CNIR AKRTARTCWGGATATTfGCA 6108-6128 16
Ctgaieous 2,27,57 LI CN2F GGGGATATGGTTGAAA1AGGT 2 6369-6360 294 0
CN2R CAOAf3GACACCATAGAGCCA 6661.6681 0
Cutaneow 3, 10, 28, 29, 77 LI C)13F AACTCIAAYATW(3CACATG 3 6140-6159 273 4
CN3R CAVGTRCSYTGGCAAATATC 64074127 24
O,tam Ge,er.1 EV LI CP62 GIWAATGAAAYTTGYAANTATCC 8 6520-6543 690 32
CP69 GWTAGATCWACAUCCARAA ml-7250 t
Ctjtumius GenesaiEV LI CP6S CARGGTCAYAÀYAATI73GYAT 8 6832.6851 250 16
CP68 GGDACRAAACCYARYTGCCA 7100-7120 41
CP66 TGGTATCTrATGGOGCAATC 38 990-1010 0
Genml EV CP69 CAATrITI’CAOTCATGTCCACA 1375-1396 0
Ctsta,eeus Geuctal agmcous LI FAP6O85F CCWGATCCHAÀIIIRRTrTGC 8 6085-6101 235 48
FAP63I9R ACATTrGIArITGTnDGGRTCAA 6319-6296 6
Qas,ecus Genetainuessal LI MYII GCMCAGGGWCATAAYAAYTGG 6 6722-6742 450 16
UYO9 CŒCCMARRGGAWACGATC 7150-7170 16
Cv 5,8.12,36.47 LI ENIF TATITCCCWACIJŒflIACTGGCIt 8 6753-6776 254 18
EN1 TCATAYTCYTCTACATGTCT 6987-7007 4
Qmeous I4 19.20,21,25 LI EN2F CTC71CAGTGGCTCATTGGT 14 6524-6543 314 0
EN2R CAW!GCATTAAITrGAGCTA 6818-6838 2
Q*meciu 9,15, I7,37 22, 23,38 LI EN3F ATCBCCWAATGATGWTATCG 23 6367.6387 293 12
EN3R TGRTrRYYCCAYAAAATRCCATT 6637.6660 32
Qga,eecs 4,43.50,60,65 LI C4 GGAGATACAGAAAATCCT 4 5728-5746 330-335 0
C4R &8ATCTcCATAGATATCTT 60624082 6
Genesal Muccml Genetal Muetsal f TTrGTTACTŒrGGTAGATAC 150
Gp& GAAAAATAAACTGTAAATCADegenetate base coae; P18,A,Ç,T 1P.,G; YT,C; W A,T; . A,C; I G, A,T 5=C,G; K=G,T: HA. T,C; VGAC; I.inoslnetable modified fnsn Eaiwood et aI, 1999 [2681
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6.1 Overview ofPCR assaysfor cutaneous HPVs:
6.1.1 fAPS9/64 primer pair:
A pair of degenerate PCR primers (FAP59/64) was designed from two relatively
conserved regions of the Li open reading ftame of most HPVs. The sensitivity and
specificity of degenerate primers depend on their degeneracy, on the conditions used for
amplification and on the region ofthe Li open reading frame chosen [228]. Studies using
degenerate primers have demonstrated a high prevalence of HPV DNA in NMSC in
RARs. The size of the generated amplicon was ± 480 bp. The fAP59 primer (5’-
TAACYGTIGGICAWCCYTATr-3’) contained two inosines nucleotides and was
degenerated at three positions, with a total degeneracy number of 8. The FAP64 primer
(5’-CCYATATCYVHCATITCICCATC-3’) also contained two inosines ami was
degenerated at four positions, from a total degeneracy number of 36 [241]. The positions
of the primers corresponded to nucleotides 598 1-6001 and 6458-6436 on the HPV-$
genome. These primers generated an amplicon of 478 bp. Primers FAP59 and FAP64
enabled amplification with PCR of a broad range of HPV types [241]. These primers
showed high sensitivity, and were optimized to allow detection of less than 10 copies of
cloned HPV genomes. The technique was also found to detect significantly higher
numbers of HPV-positive skin samples compared to the nested PCR test described by
Berkhout et al. which was aimed ofdetecting EV-HPV types (HPV-5b, 8, 9, 12, 14a, 15,
17, 19, 20, 21, 22, 23, 24, 36, 37, 38, 46, and 49) [225]. In the eight patients with various
skin tumours, HPV was found in 63 % (5/8) of tumour and in 63% (5/8) of normal skin
samples. In these eight patients, HPV-5, HPV-8, HPV-12, HPVvs2O-4 and six putatively
novel HPV types were identified. No correlation was found between specific HPV types
and histology. 0f the four healthy volunteers, three were found to harbor HPV on their
skin. The overall HPV finding in skin samples was 50% (20/40) using FAP primers as
compared to 18% (7/40) with another nested PCR test described by Berkhout et al. using
CP65/CP7O and CP66/CP69 primer pairs for cutaneous types [225,241]. These resuits
thus suggested the new method to be sensitive and generally applicable for detecting
cutaneous HPV.
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In another study using the same primer pair FAP59 and FAP64 [2361, swab
samples collected from flve different sites on the skin of renal transplant recipients,
patients undergoing dialysis, and age- and sex-matched healthy controls, were analyzed
for HPV DNA. Most individuals were found to have asymptomatic cutaneous HPV
infection, HPV DNA being detected in 85% (136/160) of ail samples. Specificaiiy, 94%
(49/52) of the renal transplant patients, 82% (23/28) of the dialysis patients, and 80%
(64/80) of the healihy controls were positive for FIPV DNA. The multiplicity of the
HPVs detected was astounding: 20 had been previously described and 30 were putatively
new types as found by cloning and sequencing of 33 samples from 13 individuals [2361.
This study also demonstrated the potential of identifying new types with FAP primers. It
also suggested that cutaneous HPV types are ubiquitous.
6.1.2 RVP2IC and F141B15 primer pairs:
The forward primer HVP2 with the sequence (5’-
ctggatccTCNMGNGGNCÀNCCNYTNGG-3’) was used and the backward primer being
the primer mixture C. The primer combination HVP2 and C amplified the group ofHPV
type 4, 60 and 65 DNA poorly. HPV-4 and IIPV-65 are closely related to each other,
with NPV-60 being more distant [255]. To specifically amplify these types, additional
primers were designed. The forward primer f14 (5’-
ctggatccWGATGAYAAYAGAMWGGATG-3’), and backward primer B15 (5’-
ctggatccATWCCRTTRTTYGYWCCYTG-3’) corresponded to positions nt 5767-5768
and nt 6339-6320 on the HPV-4 genome, respectively, and generated a PCR produet of
573 base pairs. In a total of 11$ biopsies from skin lesions of 46 RAR, HPV DNA was
detected in 62% (31/50), and 56% (14/25) from SCC and BCC biopsies, respectively.
Nine putative new HPV types were detected with these primers [228].
In a subsequent study, these highly degenerate primers were spiit into a number of
less degenerate primers [253]. The same samples analyzed above were tested using 16
different primer combinations foilowed by semi-nested amplification, cloning and
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sequencing of the HPV-specific products. HPV DNA was demonstrated in 65% of SCC
lesions and in 60% of BCC samples. A number of different HPV types, the majority
belonging to the high-risk genital I{PVs as well as EV-related I{PV types were detected
[253].
6.1.3 F and G primer sets:
Many primer pairs have been described for the detection of NPV in warts
[326,327]. However, these primer sets have failed to consistently detect NPV DNA in
skin cancer. Berkout et al. [225] designed a specific PCR method to detect the group of
EV-associated papillomavirus types in 8CC patients with different primers (F and G).
The first primer set (F) consisted of two degenerate primers CP65/CP7O, located in the
late Li ORF (CP65: 5’-CARGGTCAYAAYAATGGYAT-3’, CP7O: 3’-
AAYTTTCGTCCYARAGRAWATTGRTC-5’). The annealing sites in the NPV-8
genomic sequence corresponded to positions nt 6832-6851 and nt 7273-7298 [256]. The
second primer set (G) consisted of two degenerate primers CP66/CP69, located in the Li
ORF (CP66: 5’-AATCARYTGTTTRTTACWGT-3’, and CP69: 3’-
GWTAGATCWACATYCCARAA-5’). Their respective annealing sites were at positions
nt 6862-6991 and nt 723 i-7250 of HPV-8 [225]. In 53 biopsies with 8CC from RTRs,
HPV DNA was detected in 81% (43/53) of samples. The HPV types included EV
specific as well as 6 putative new EV-related HPV types [2251.
6.1.4 BD and AM primer sets in human:
These two sets of primers covered adjacent sequence stretches within a highly
conserved region of the Li open reading frame of papillomaviruses [2]. The flrst set
(HD) consisted of i6 different primer combinations described by Shamanin et al.
(forward/backward) including AifBi, FiO/B5, Fi2/B5, AiIB6, F10/B6, Fii/B6, F12/B6,
F2i/Bil, F22/Bli, f23/Bii, F24/B11, F2iJB12, F22/Bi2, and F241B12 [253], as well
as two additional combinations, FWP2fHVP7 and HVP2/HVP9, described by de Villiers
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et al. [2,253]. The second set ofprimers (AM) designed to detect EV-specific HPV types
consisted ofprimers CP65/CP7O for the initial amplification rounds, followed by a nested
amplification with primers CP66/CP69 [225,237]. HPV-3$ specific primers were also
selected in the region of the Li open reading frame in which the CP66/CP69 primer is
located. The forward primer was 5 ‘-ttggatccTGGTATTTTATGGGGCAATC-3’ located
at nt 990-1010 of HPV-38 and the backward primer was 5’-
ffggatccCAATTTTTCAGTCATGTCCACA-3’ located at nt 1375-1396 of HPV-3$. A
total of 68 skin biopsies collected ftom 25 RARs over a period of 12 years (15 warts, 7
actinic keratosis, 7 verrucous keratosis, 2 keratosis, 1 keratoacanthoma, 2 BCCs, 22
SCCs and 11 intra-epidermal carcinomas (ffiCs) ) were analyzed using the same primers
(HI, AM). Amplified DNA obtained using the first set of primer was obtained for 93%
(14/15) of samples from warts [2].
Table (6): HPV DNA positive using the both sets ofprimers.
Lesions RD primer (%) AM primer (%) Total
Warts (n15) 14 (93) 15 (100) 15 (100)
Keratosis (n=17) 4(24) 10(59) 11 (65)
IECs*(n=11) 5(45) 7(64) 10(91)
SCCs (n=22) 11 (50) 1$ (82) 20 (91)
*LEC5 Intra-epidermal carcinomas
From de Viilier et ai, 1997 [2].
The amplified DNA products obtained using the first set of 1$ distinct primer
combinations were cloned and sequenced. HPV DNA was detected in 14 of 15 (93%)
samples from warts. The HPV types detected includes HPV-1, 2, 4, 10, 27, 57, 63, and
vslO2-4 (HPV 17-related [22$]). Only 2 ofthe 7 biopsies from actinic keratosis samples
contained detectable HPV DNA, i.e., HPV-57 and DL78, a putative new type. 0f the 7
verrucous keratosis, one contained HPV-23 DNA and one seborrhoeic keratosis
contained HPV-7. The keratoacanthoma was negative for NPV. Forty five percent (5/11)
of IECs contained HPV DNA. Types detected in IEC included HPV-57 and 3 putative
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new HPV types: DL4O, DL7$ and DL 100. fifty percent (11/22) of SCCs harboured
HPV-1, 11, vs206-2 HPV 4$-reÏated [23$] and 7 putative new HPV types: DL17, DL2O,
DL27, DL4O, DL82, DL$3 and DL84 [2J. The presence ofIIPV-1, 2, 7, 11, 23, 27, 57,
and 63 DNA demonstrated with the first set of primers was confirmed aller cloning and
sequencing of the nested PCR products. Amplification with the second set of primers
resulted in the detection ofHPV DNA in ail 15 samples from warts [2]. A combination of
the resuits obtained with the 2 sets of primers demonstrated HPV DNA sequences in
100% (15/15) ofwarts, 59% (10/17) ofkeratosis, 91% (10/11) ofIEC lesions and 91%
(20/22) of SCC samples. No HPV DNA could be detected in either ofthe 2 BCC samples
[2]. In opposite to FAP primers, nested PCR was necessary to reach these resuits.
In another study using the same primers [237J, 21 samples ftom 14
immunocompetent patients were examined. Extracted cellular DNA was amplified by
PCR using either one or both sets of degenerate primers BD and AM [237]. Nine percent
(2/21) ofsamples were positive by HD and 38% (8/21) by AM (Table 7) [237].
Table (7): HPV DNA in tumors and per-lesional skin ftom immunocompetent patients
using both primer sets.
Lesions lTD (%) AM (%)
Self-healing epithelioma (n=1) 0 (0) 0 (0)
Sebaceous epithelioma (n=1) 0 (0) 0 (0)
Verrucous keratosis (n=1) 1 (100) 1 (100)
Actinic keratosis (n=2) 1 (50) 1 (50)
*ffiC (n=6) 0 (0) 3 (50)
BCC (n=3) 0 (0) 0 (0)
SCC (n’1) 0(0) 0(0)
Uninvolved peri-lesional skin (n=6) 0 (0) 3 (50)
*lECst Intra-epidermal carcinomas
From Astori et aI. 1998 [237].
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6.1.5 GP5+/GP6 and CP65 I CP7O +CP66 1CP69:
Investigators analyzed skin samples ftom 54 psoriatic patients to define the
spectrum of HPV types involved and to test if detection of HPV was influenced by
psoralen ultraviolet A therapy compared with 42 healthy immuncompetent individuals
undergoing nevus excisions ( mean age 43.0 years range 16-79 years). Patients were ail
immunocompetent individuals with a mean age of 48.5 years (17-74 years). DNA
preparations were examined for the presence of HPV sequences by PCR analysis with
primers chosen to detect a broad spectrum ofHPV types. The two primer sets used were:
GP5+ (5’ -TTTGTTACTGTGGTAGATAC-3’) and GP6+ (5’-
GAAAAATAAACTGTAAATCA-3’) [258], designed for HPV types infecting the
genital mucosa, and CP65 / CP7O and CP66 /CP69 (described above) [225] in a nested
PCR for the detection of EV-associated papillomaviruses. They could detect HPV
sequences in skin lesions of 83% of tested patients. In contrast, HPV DNA was only
demonstrated in 19% of skin samples from 42 dermatologically healthy
immunocompetent individuals.
Table (8): Detection ofHPV DNA in samples of normal and psoriatic skin.
particpants GP5+/GP+6 CP70165-69/66 HPV5 Specific HPV36 Specific Total
(%) (%) (%) (%) (%)
Psonatic skin 0 (0) 38 (70) 16 (30) 28 (52) 45 ($3)
(n=54)
Healthy skin 0 (0) 6 (14) 0 (0) 4 (10) 8 ( 19)(n=42)
From Weissenbom et al. 1999 [259].
Sequence analysis ofthe PCR amplicons revealed 14 HPV types, ail belonging to
EV-reiated papillomaviruses. Only one case had a putatively new human papillomavirus
type related to those of genital viruses. The most prevalent HPV type in this report was
HPV-36, found in 62% of patients positive for human papillomavirus DNA, foliowed by
HPV type 5 (38%) and HPV-3$ (24%). Multiple infections with two to five different
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HPV types could be detected in skin samples ftom 63% ofthe patients tested. The overail
HPV detection rate did not differ significantly between patients subjected to psoralen
ultraviolet photochemotherapy or locally treated with topical preparations (77% vs. 89%)
[259]. Using the nested PCR approach with primers CP7O/65 and CP69/66,
papillomavirus sequences could be found in 70% (38 /54 studied biopsies) of patients,
indicating a high prevalence ofpapillomavirus infections in psoriatic skin. No HPV DNA
could be detected in psoriatic lesion using the single-step PCR test with primers
GP5+/GP6+, specific for HPV types infecting the genital mucosa [259].
GP5+ and GP6+ were used in another study [2601 as well as specific primers pair
to amplify virus types HPV-1 1, 16, 1$ and 33 by multiplex PCR (table 5). Another
specific primers pair was used to amplify types 2, 5, 8, with another multiplex PCR
[223,252,260,261]. They examined samples ftom 108 immunocompetent patients with
benign and malignant skin lesions, and HPVs were detected in 27% (29/108) of samples.
HPV-$ and HPV-18 were the most frequent types (detection rate of 62% and 48%
respectively) (table 9,10) [260].
Table (9): HPV primer sequences used to detect HPV types 1, 2, 5 and 8.
HPV type Primer Sequence Position Size bp
1 P1 AGTCTTATGAGGTACCGGAAATAGAAG 383-409 136
1 P2 ATGCACTCTTCTCCGTTGACACAACCTC 520-490
2 P1 ATGGTTGGAGCTAGAGGA1TGCG 159-183 303
2 P2 AACTAGTAATGCCTCCTCTCCTCC 463-43$
5 P1 CTCTAATACCAAATTCTGTGGCGT 616-640 279
5 P2 GAGGAACGCCTGGAAGGGAATCTG 894-$70
$ P1 CGGGCAGGACAAGGCTTCATATTACACAC 200-230 220
$ P2 ACAACAACGACAACACGCAGTAACAAC 420-3 93
From Dano et al 1982 [108].
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Table (10): Detection ofHPV in human skin lesions by PCR.
Lesions HPV Positive (%)
BCC(n=72) 22(31)
SCC (n=23) 3 (13)
Bowenoid lesions (n=5) 2 (40)
Precancerous (n=$) 2 (25)
Total (n=1O$) 29 (27)
From Biliris et al. 2000 [2601.
6.1.6 MYO9/11 and C? primers:
Analysis of HPV DNA on the skin has also been carried out using two different
sets of Li consensus primers and two sets of non-degenerate primers in nested PCR
assays.
MYO9/i 1 degenerate primers were shown to detect a broad spectmm of mucosal
HPVs [249], while primers CP65, CP66, CP69 and CP7O (CP primers) allowed
amplification of ail EV-associated cutaneous HPVs [225]. Primer sets MY5-1/2, MY5-
3/4, MY$-1/2 and MY8-314 were derived from the MYO9/1 1 and MYN9/10 region ofthe
HPV-5 and NPV-$ genomes, respectively [262].
Table (12): frequency ofHPV DNA detection in cutaneous SCC using different PCR.
Degenerate primer Non degenerate primer Ail PCR assays (n=32)
MY CP (n=32) MY5 MY8 (n=20)
50% (16) 45%(9) 69% (22)
from Meyers et al. 2000 [262].
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32 cutaneous biopsies of $CC from 24 patients were analyzed for HPV DNA
detection using both consensus PCR assays with degenerate primers and PCR assays with
non-degenerate primers derived ftom HPV types 5 and 8. HPV DNA was found in 50%
of SCC specimens using degenerate primers. The rate of HPV-DNA-positive specimens
increased to 69% when PCR assays using non-degenerate primers were applied to the
same set of samples [262].
Table (11): Sequences ofoligonucleotides used as primers ofspecific PCR products.
Primer Sequence Length, bp
MYO9 CGTCCMARRGOAWACTGATC 450
MY1 1 GCMCAGGGWCATAAYAATGG
MYN9 GTfACTGTKGTWGAYACYAC 370
MYN 10 TCY1TARATYAACMTYCCA
CP65 CARGGYCAYAAYAATGGYAT 460
CP7O AAYTTFCGTCCYARAGRAWATTGRTC
CP66 AATCARMTGTFFRTACWGT 380
CP69 GWTAGATCWACATYCCARAA
MY5- 1 GCCCAGGTCATAATAATGG 464
MY5 -2 CTGCCTAAGGAATATTGATC
MY5-3 ATCACAGTGGTGACAACAC 380
MY5-4 TCAGTfAAATCTACATCCCA
MY8-1 GCCCAGGGTCATAATAATGG 464
MY8-2 CTGCCTAATGAATATTGATC
MY8-3 GTCACTGTGGTAGACAACAC 480
MY8-4 TCTGTAAGGTCCACATTCCA
* Degenerate code: Y=C,T; MC,A; W=A,T; K=G,T; RA,G; S=C,G.
From Meyers et al. 2000 [262].
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6.1.7 HVP2JB5 and CP primers:
In one study [254J, 4 estabiished oligonucleotide primer pairs (HVP2/B5,
F14/B15, MYO9/i 1, CP62/69) described above, were compared [254]. These primers are
ail located within the conserved region of Li [225,228]. The degenerate primer pair
HVP2JB5 was described by Shamanin et al. to detect HPV from ail groups with the
exception of the phylogenetic clade comprising HPV-4, 48, 50, 60 and 65 for which the
primer pair fi4/B15 was used [228,253]. The primer MYO9IMY1Y was originaliy
designed by Manos et ai. for the detection of HPV in genitai lesions [249] but has aiso
been wideiy used to anaiyze skin lesions [263,264]. finally, Berkhout et al. have
described severai primer pairs for nested PCR which were designed to detect EV HPV
types [225,243]. 0f these, one particuiar set comprising CP62/69 as an outer primer pair
and CP65/68 as an internai nested pair was considered to be particularly sensitive for
detecting HPV in skin biopsies from both immunocompetent and immunosuppressed
individuals [2251.
Table (13): Detection ofHPV DNA with each degenerate primer sets.
Disease HVP2IB5 FA14/B15 MYO9I11 CP62169
Warts(n=22) 15 0 12 10
5CC (n=19) O 0 0 8
BCC(n=2) O O O O
Ano-genitai carcinoma (n=5) 3 0 3 0
Normai (n=1) O O O O
Total (n=49) 1$ (37%) 0 (0%) 15 (31%) 1$ (37%)
From Surentheran et ai. 1998 [254].
The sensitivity and specificity of three published degenerate primer sets
(HVP2/B5 and F14/B15; MYO9/MYY 1; CP62/69 outer and CP65/68 nested primer pairs)
were evaluated in PCR reactions with serial dilutions of 12 representative cloned HPV
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types. These primers sets were used to detect HPV DNA in 49 benign and malignant
lesions of cutaneous and mucosal origin from immunosuppressed, immunocompetent,
and EV patients. Resuits with each primer pair were compared [254J. HVP2IB5 was the
best pair for detecting HPV in warts.
6.1.8 fAP6O$5/6319:
In this study, DNA sequences from the Li gene were aligned within the region
between the original fAP59/64 primers ofknown cutaneous HPV types described in the
i996 HPV Sequence Database compendia (Myers, 1996) and candidate HPV-92 and
HPV-93 (Forsiund et al., 1999). Conserved fegions suitable for nested PCR were
identified [256]. Two regions with a relatively high degree of nucleotide sequence
homology were identified. A forward primer FAP 6085F (5’-
CCWGATCCHAATMRRTTTGC-3’) and a reverse primer FAP 63 i9R (5’-
ACATTTGIAITTGTTTDGGRTCAA-3’) were designed [256]. A total of 56 biopsies
were tested from 51 patients: 64% (3 5/56) were positive for HPV using FAP6O$5/63 19,
including 62% (16/26) ofBCCs, 43% (7/16) of 5CC, 93% (13/14) ofAK [2561.
6.1.9 Others primers:
In one study [266], a panel of degenerate primers targeting Li to detect mucosal,
cutaneous, and EV HPV types with high sensitivity and specificity. These pnmers
included MYO9/MY1 1, GP5+/GP6+ for mucosal HPV types, HVP2fB5 for cutaneous
HPV types [253] combined with three pairs of nested primers. The latter were designed
from published sequence data to detect the following IIPV groups [267]: A2
(CN3F/CN3R), A4 (CN2F/CN2R), and E (CN1f/CN1R). The cutaneous group B2 was
detected using a single round of PCR with primer pair C4F/C4R. EV-associated NPV
types of group Bi were detected with the nested primer pairs CP62/69 and CP65/CP6$ as
described above [225]. Three additional primer pairs were designed nested within
CP62/CP69 amplicon to detect the major EV-HPV clusters ai (EN1FIEN1R), a2
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(EN2fIEN2R), and bl/b2 (EN3F/EN3R) (table 5) [226]. In this study, biopsies from
benign and malignant cutaneous lesions were analyzed for the presence of HPV DNA
from patients treated with high-dose of ultraviolet A. HPV DNA was detected in 75%
(15/20) ofNMSC, 41.2% (7/17) of dyspiastic PUVA keratosis, 80% (4/5) of skin warts,
and 33% (4/12) ofPUVA-exposed normal skin samples [266]. This approach allowed for
the detection of a wide spectmm of types but is fastidious, necessitating several reactions
per specimen.
In general, fAP59/64 primer pair was shown to be the best primer pair to detect
cutaneous HPV types. It is also the most frequently used primer pair in epidemiological
investigations on cutaneous HPV infection [236,228,24 1]. These primers also
demonstrated their potential to identify novel types. The second usefril primer pair is
HVP2/B5 as it showed to be the best for detection ofHPV in warts [254].
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$tudy objective:
b describe the detection rate of cutaneous HPV types in individuals living in
Canada.
b describe the spectrum ofHPV types infecting the normal skin.
To determine the agreement between primer pairs to detect cutaneous HPV types.
To compare the rate of detection of cutaneous HPV types between individuals
with a renal allografi, squamous celi carcinoma, actinic keratosis and in healthy
individuals.
To assess the ftequency of multiple infection on the skin of individuals with skin
lesions.
‘ To describe nove! types ofHPV.
b compare c!oning and direct PCR sequencing for the typing ofHPV amplicons.
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Abstract (word count = 250)
Objective. We compared the diagnostic yield ofPCR using fAP59/64 and HVP2/B5 Li
consensus primers for the detection and typing of human papillomavims (HPV) in skin
swab specimens.
Design. Cross-sectional study.
Methods. IIPV isolates were typed by sequencing amplicons directly ami afier cloning.
Resuits. Seventy-five (92.6%) of 81 subjects provided samples that could be analysed
with PCR (34 healthy controls <50 years old, i3 healthy controls 50 years olU, 12 with
actinic keratosis (AK), $ with squamous celi carcinoma ($CC), 8 renal transplant
recipients). NPV DNA was detected more frequently with FAP59/64 (68/75, 91%) than
with HVP2/B5 (9/75, 12%) (p<O.00i). Agreement of typing resuits between PCR
sequencing directly or afler cloning of FAP59/64-generated amplicons was fair (mean
kappa 0.56±0.19, 95%CI: 0.46-0.65). HPV types were sometimes identified only by
direct sequencing and not afler cloning of FAP59/64 or HVP2/B5 amplicons. HPV
species 1 and 2 of the Beta-papillomavirus genus were associated with the presence of
AK (OR=24.8, 95%CI: 2.3-262.6). However, seven of eight participants with SCC were
infected with putative novel types and only one with HPV species 1 ami 2 of the Beta
papillomavirus genus. fA5 1 was detected more frequently in participants with AK or
SCC than in healthy participants (OR=i9.7, 95% CI: 2.1—186.5). A greater number of
HPV types per sample was found in individuals with AK or SCC (p=O.O46) or AK alone
(p=O.O2), than in healthy participants.
Conclusion. HPV infection in the skin could 5e better evaluated with a combination of
primefs and sequencing strategies. Nove! putative types were frequent!y detected in SCC.
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Introduction.
Human papillomaviruses (HPV) are ubiquitous viruses that infect the skin of the
majority of immunocompetent and immunocompromised individuals (Antonsson et al.,
2000; Astori et al., 199$). Mthough HPVs have been clearly shown to cause anogenital
squamous carcinomas (Bosch et al., 2002), their role in the pathogenesis of non
melanoma skin carcinoma (NMSC) remains controversial (de Villiers et al., 1999; Kiviat,
1999). A broad spectrum ofBPV types has been reported in NM$C, many ofthese being
previously uncharacterised (Purdie et al., 1999; Shamanin et al., 1996; Antonsson et al.,
2000). HPV DNA has been detected in up to 83% of immunocompetent individuals with
NMSC (Sterling, 2005; Harwood et ai, 1999; Forsiund et al., 2003; Harwood et ai,
2000). from 40% to 100% of actinic keratosis (AK) also contain NPV sequences
(Harwood et al., 199$; Sterling, 2005; Harwood et al., 2000; Shamanin et al., 1996;
Biliris et al., 2000). Differences across studies of prevalence rates and diversity of HPV
types in skin lesions seem to reflect the lack of appropriate primers and probes to detect
efficiently ail cutaneous HPV types via PCR (Kiviat, 1999; Harwood et al., 199$;
Kawashima et al., 1990).
Consensus PCR assays have been instrumental in demonstrating the complexity
of cutaneous HPV infection and in detecting novei genotypes (Forsiund et al., 2003;
Astori et al., 1998; Forslund et al., 1999; Harwood et ai., 1999; Harwood et al., 2004;
$hamanin et al., 1996; Berkhout et al., 1995; De Jong-Tieben et al., 1995). The most
commonly utiiised consensus primers for cutaneous genotypes target highiy consewed
sequences in the HPV Li gene (Forslund et al., 1999; Forslund et al., 2003; Forslund et
al., 1999; Antonsson et al., 2003; Harwood et al., 2004; Antonsson et al., 2000; Shamanin
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et al., 1996; Berkhout et al., 1995; Berkhout et al., 2000). fÀP59164 and HVP2/B5
consensus primers amplify a broad spectrum of HPV types infecting the skin, can detect
as low as 1-10 copies of HPV DNA and have been utilised in several epidemiologic
studies (Forsiund et al., 1999; Forsiund et al., 1999; Shamanin et al., 1994; Shamanin et
al., 1994; Antonsson et al., 2003; Forslund et al., 2003; Antonsson et al., 2000; $hamanin
et al., 1996; Surentheran et al., 1998). Few studies have compared the performance of
consensus PCR assays for the detection and typing of cutaneous types and none have
compared FAP59164 with HVP2/B5 primer pairs (Harwood et al., 1999; Meyer et al.,
2000; Surentheran et al., 1998; Forsiund et al., 2003; Astori et al., 1998).
In the present report, we compared consensus primer pairs fAP59/64 and
HVP2IB5 for the detection and typing ofHPV DNA in epithelial celis collected from the
skin. We also evaluated the agreement between sequencing directly and afier cloning
HPV amplicons generated with cadi PCR assay, to identify HPV types detected in the
skin. The detection rate of cutaneous HPV infection was also estimated in Canadians, a
population with a high incidence of NMSC.
67
Materials and methods:
Study population. Samples were colÏectedftom Januaiy 2003 to December 2004 from
81 subfects recruited in Montreat. Heatthy individuals without current or past histoiy of
5CC or AK and 50 years old (n=13), immunocompetent individuals with AK (n=13),
and immunocompetent individuals with cutaneous 5CC (n=11) were recruited
consecutiveÏy from an oulpatient dermatology-oncology clinic. HeaÏthy individuals
without current or past histoiy of 5CC or AK and < 50 years old (n=36) and renal
transplant recipients (12=8) were recruitedftom the Centre Hospitalier de Ï ‘Université de
Montréal. Alt participants with AK, SCC were older than 50 years of age. Individuals
with a reiial allografi had been graftedfor at least two years, kid no current or past
histoiy of wart, 5CC or AK, and were older than 50 years of age. The diagnosis of alt
cutaneaus lesions was confinned by histopathology. The Ethics Committee of the Centre
Hospitalier de t ‘Université de Montréal approved the research protocot. Each
participantprovided informed consent at enroilment.
Specimen collection and processing. Epithelial celis from the skin were collected with
pre-wetted (sterile water) Dacron-tipped swabs (Fisher Scientific, Nepean, Ont, Canada)
which were drawn back and forth four times over the forehead skin within an area of
5x15 cm for individuals without skin lesion and over the lesion within a similar surface
for participants with cutaneous lesions (Antonsson et al., 2000; Antonsson et al., 2003).
For individuals with a skin lesion, the sample was thus from the surface ofthe lesion and
from perilesional normal skin. Each swab was immersed in tubes containing 500 j.tl of
Preservcyt (Cytyc Corporation, Boxborough, MA), was agitated and then discarded.
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Specimens in Preservcyt were centrifuged at 13,000 x g for 15 min at 22°C and
resuspended in 300 i.il of 20 mM Tris buffer (pH 8.3). DNA was purified using the
Master pure procedure (Aho et al., 2004). Five jil of each sample was tested for the
presence of human 3-globin DNA with a PCR using PCO4/GH2O primers (Bauer et al.,
1991; Coutlée et al., 1997).
Consensus Li PCi? assays. Five jil ofprocessed sample was amplified in each assay in a
9600 Thermal Cycler (Perkin-Elmer Cetus, Montreal, Canada) in a 100 .rl reaction
volume containing 10 mM Tris-HCI [pH 8.3], 50 mM KC1, 5 U ofAmptiTaq Gold DNA
polymerase (Roche Diagnostic Systems, Mississauga, Ont.), 3.5 mM MgCl2, and 200 1.tM
of each dNTP. For FAP59/64 PCR, purified DNA was amplified with 3 j.iM of cadi
primer FAP59 (5’-TAACWGTIGGICAYCCWTATT-3’) and FAP64 (5’-
CCWATATCWVHCATITCICCATC-3’) at 95°C for 10 min followed by 45 cycles of
1.5 min at 94°C, 1.5 min at 50°C and 1.5 min at 72°C (Forslund et al., 1999; Antonsson et
al., 2003). For HVP2fB5 PCR, purified DNA was amplified with 0.75 .tM of each primer
HVP2 (5’-TCNMGNGGNCANCCNYTNGG-3’) and B5 (5’-
AYNCCRTTRTTRTGNCCYTG-3’) (Shamanin et al., 1994; Shamanin et al., 1994;
$hamanin et al., 1996) at 94°C for 10 min followed by 45 cycles of amplification for 1
min at 94°C, 2 min at 52°C and 1 min at 72°C, and a final step of 6 min at 72°C. For each
PCR mn, amplification buffer and human fibroblast DNA negative controls were
included. Measures to avoid false positive reactions due to contamination were followed
(Coutlée et al., 1997). HPV-5 or HPV-8 plasmids served as positive controls for both
assays that reached an equal level of sensitivity in vitro (data flot shown).
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HPVDNA typing by PCR-sequencing. HPV amplicons were visualised by migration on
a 2% agarose gel stained with ethidium bromide. The presence of HPV amplicons was
suspected by size determination (amplicons migrating at ±650 bp for HVP2IB5 and at
±480 bp for FAP59/64). Amplicons were purified with the QlAquick gel extraction kit
protocol (Quiagen Inc., Mississauga, Ont). Double-stranded PCR-sequencing was done
directly on amplicons and also afler cloning of amplicons in a vector. To this end, PCR
products were cloned using the TOPO TA cloning kit (Invitrogen, Cafrsbad, CA)
(Mayrand et al., 2000). Five recombinant clones per sample and per primer pair were
sequenced. To conflrm results obtained when a HPV type identified by direct sequencing
could not be identified in cloned HPV amplicons or when the first five clones yielded
more than one type, 5 additional clones were sequenced. Plasmid DNA from transformed
clones was then ffirther purified using the QlAprep Spin Miniprep system (Quiagen Inc.)
according to the manufacturer instructions. Double-stranded PCR-sequencing was done
with forward and reverse primers using a fluorescent cycle-sequencing method (BigDye
terminator ready reaction kit, Perkin-Elmer) on twenty ng of purified DNA (Yamada et
al., 1997). Cycling parameters were 25 cycles at 96°C for 10 sec, 50°C for 5 sec and
62°C for 4 min. Sequence analysis was performed on an ABI Prism 3100 Genetic
Analyzer system at the Centre de Recherche du CHUM.
HPV sequences were compared with sequences of known types and novel
putative types in the EMBL and GenBank databases using the BLAST server
(hnp://www.ncbi.nlm.nih.gov/blast/blast.cgi). Isolates sharing 90% homology in the
partial nucleotide Li sequence were considered to belong to the same type. Guidelines
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from the Papillomavirus Nomenclature Committee were followed in deflning novel
putative HPV types since only a region of Li was analysed with both primer pairs (de
Viiliers, 2001). An isolate was considered as a new putative type if the partial Li
sequence displayed <90% homology with known types. HPV types were classified into
the various papillomavims genus recently described (de Villiers et al., 2004). Novel
putative types were classified into papillomavims species when they shared between 71%
to 89% nucleotide identity within the partial Li sequence with a known type of that
species (de Viiliers et al., 2004). HPV Li DNA sequences were ail aligned using Clustal
X 1.8i (Altschul et al., 1990).
Statistical analyses. The cmde percentage of agreement (concordance) between sampling
methods was the percentage of pairwise samples for which results were identical
considering the presence of HPV DNA irrespective of type or the presence of each type
individually. The modified Wald method was used to calculate 95% confidence intervals
(CI) around binomial proportions (Agresti and Couli, 199$). The unweighted kappa (K)
statistic was calculated to adjust for chance agreement between sampling methods (Fleiss,
i 981). Proportions were compared with the z stafistical test. Categorical variables were
compared with the Pearson’ s chi-square test or the Fisher’ s exact test, depending on the
sample size. b identify potential associations, simple logistic regression analyses were
performed to compute odds ratios (OR) and 95% confidence intervals (95% CI). The
number of types per sample was compared between healthy participants and those with
skin lesions using the Mann-Whitney rank sum test. Double-sided P values of 0.05
were considered significant.
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Resuits
Comparison of FAP59/64 and HVP2/B5 primers for HPV DNA detection. f3-globin
DNA was detected in extracted DNA from 47 (95.9%) of 49 swab samples from healthy
individuals, 12 (92%) of 13 samples from those with AK, $ (72.7%) of the 11 samples
from those with SCC, and $ (100%) of $ samples from renal transplant recipients (p>
0.05). Only participants with J3-globin-positive samples were considered for the analyses
described below. HPV DNA, irrespective of types identified by sequencing, was detected
more frequently with FAP59/64 than with HVP2/B5 in ail subject categories defined by
lesion status (Table 1). 0f the 47 swab samples from healthy individuals without skin
lesion irrespective of age, 41(87%) and 4 (9%) contained HPV DNA with FAP and
HVP2 primers, respectively (j<O.OO 1).
IIPV typing with PCR-sequencing of FAP59/64 and HVP2IB5 amplicons. PCR
sequencing of amplicons generated with fAP59/64 primers revealed the presence of 77
different types (22 known types, 55 putative novel types) in 75 samples, whereas those
generated with HVP2/B5 primers identified only $ types (3 known types, 5 putative novel
types) in the same set of sampies (p<O.001). The list ofthe most frequentiy detected types
with fAP59/64 and of all types detected with HVP2IB5 is provided in Table 2. Three
putative novel HPV sequences (LIOl, L102, L103) were detected with FAP59164
primers (Table 3). In 67 specimens, from 1 to 10 types (mean 2.3±1.8 types, median 2
types) were detected with FAP59/64 only. In two specimens, from 1 to 2 types (mean
1.5±0.7, median 1.5 types) were detected with HVP2/B5 only. However, the latter two
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samples contained HPV types that were detected only by FAP59164. FAP59164 detected
in at least one specimen one ofthe 77 types identified in this study while HVP2/B5 was
negative (median 2.0 samples, mean 2.0±1.2 samples). Using PCR-sequencing of cloned
amplicons generated with FAP59164 primers, a median of 1 type per sample (range of 0-
10, mean of 1.43±1,76, 95% CI 1.10-1.76) was identified in contrast to a median of O
type (range of 0-2, mean of 0.06±0.31, 95% CI 0.01-0.12) with PCR-sequencing of
cloned amplicons from I{VP2/B5 primers (p<0.001). The difference between the number
of types per sample detected with FAP primers with sequencing of HPV amplicons or
afier cloning was significant (p<0.001).
HPV amplicons migrating at the appropriate size were sequenced directly and
also aller cloning. Typing resuits obtained with both sequencing strategies were
compared for each primer set. For each categoly of participants based on disease status
(healthy, AK, SCC, immunosuppressed individuals), there was no difference in the
detection of HPV DNA sequences by sequencing directly or aller cloning amplicons
generated with FAP59/64 or IIVP2/B5 primers (p>O.22, data not shown). The percent
agreement between direct sequencing of amplicons and sequencing aller cloning of
amplicons for each primer pair is provided in Table 2. Although agreement with
FAP59/64 primers was above 93% for each type, the low kappa value between typing
procedures suggested at most a fair agreement beyond chance (mean c 0.56±0.19,
95%CI: 0.46-0.65). PCR-sequencing aller cloning was more efficient than direct
sequencing for 15 types when amplicons had been generated with FAP59/64 (Table 2). In
seven samples containing one (n=1) or several types (n=6), an HPV type was detected by
direct cloning of FAP59/64 amplicons but only HPV-unrelated sequences were cloned
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and sequenced (data flot shown). Similarly, IIPV types 25, fA23, FA1 12, VS92. 1 were
detected only by direct sequencing of amplicons generated by HVP2/B5 while
sequencing of 10 clones did flot reveal the presence ofHPV DNA sequences.
Association between IIPV infection and skin disease. The influence of age on the
detection rate of NPV in skin swab samples was assessed in the 47 healthy individuals
without skin lesions (Table 1). HPV DNA was detected as frequently in skin samples
from healthy individuals younger and older than 50 years of age (p=O.54). In healthy
individuals (Table 4), HPV fA127 was detected more frequently in participants> 50
years (23% versus 0%, p=0.02).
When individuals with a renal allografi, AK and SCC were compared to healthy
individuals over 50 years old, there was no significant difference in the detection rate of
HPV DNA (Table 1), healthy controls being frequently infected by HPV. HPV types
within species 1 and 2 of the Beta-papiilomavirus genus were the most common, being
detected in 27 (36%) participants (Table 4). These two species considered together were
significantly associated with the presence of AK (OR=24.8, 95%CI: 2.3-262.6). Neariy
ail skin swab samples obtained from participants with AK contained at ieast one type
belonging to these two species. Only one participant with SCC was infected with an
isolate belonging to the Beta-papiilomavirus genus, ail other samples contained putative
nove! types (table 4). Alpha papillomavims species 2, usually found in benign lesion (de
Viliiers et al., 2004), were detected in only one participant with AK concurrently with an
HPV-5 isolate, a type belonging to the Beta-papiliomavirus genus.
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As shown in Table 4, the most ftequently detected HPV isolates in participants
with AK or $CC were putative types FA5 1 and fA62 (Table 4). HPV FA5 1 was detected
in samples from 3 (38%) of 8 individuals with SCC as opposed to O (0%) of 13 older
healthy individuals (p=O 04). By combining resuits obtained for both skin diseases, FA5 1
was detected in 6 (3 0%) of 20 individuals with lesions as opposed to 0 (0%) of 13 healthy
controls older than 50 years (p=0.06). Since KPV FA5 1 was detected only in young
healthy participants, we combined ail healthy participants irrespective of age and found
FA5 1 was detected significantiy more ftequently in participants with AK or SCC (6
(30%) of 20) than in ah healthy participants (1 (2.1%) of 47), a difference that was
statistically significant (OR=19.7, 95% CI: 2.1—186.5;). However, the number of
participants in our study was small and this association should be confirmed in a larger
study. There was no clear association between skin disease status and HPV detection for
the other types.
The association between the number of types identified by PCR per sample and
skin disease or immunodeficiency status was then investigated (Table 5). Overail, median
number of types was 1 (mean of 1.7±1.9, 95%CI: 1.3 — 2.0; range 0— 11). The burden of
HPV infection measured as the number of types per sample (Table 5) was significantly
greater in renal transplant recipients than healthy participants older than 50 years
(p=O.O5). There was no difference between the burden of HPV infection in healthy
individuals below or above 50 years of age (p=O.8l). When healthy participants were
compared to participants with AK or SCC, a greater burden ofHPV infection was found
in individuals with skin disease (p0.046) or with AK alone (p0.02).
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Discussion
Our evaluation revealed that FAP59/64 primers detected a greater number of
samples positive for HPV and also a greater number of HPV types per sample. The
fragment generated with FAP primers (nucleotide positions 5981 to 645$ of HPV-8) is
nested within the amplicon generated with HVP2JB5 (nucleotide positions 5835-648 1 of
IIPV-8) (Shamanin et al., 1996; Forsiund et al., 1999). Amplification efficiency may
have been better with FÀP59/64 primers because they amplified a smaller DNA
fragment. FAP59164 primers amplify less efficiently types 1, 2, 41, and 63 (Forsiund et
al., 1999) while HVP2IB5 amplify less efficiently types 4, 48, 50, 60 and 65 (Surentheran
et al., 1998). The sensitivity ofFAP59/64 and HVP2IB5 primers can be increased using
nested PCR (Forsiund et al., 2003; Shamanin et al., 1996), a strategy that was not used in
this evaluation. In our study, even if more samples were found to 5e HPV-positive with
FAP59/64 than HVP2/B5, the combination ofresuits obtained with both primer pairs was
more informative of the diversity of cutaneous HPV infection. Several studies have
demonstrated that combined primer panels allow for a more comprehensive evaluation of
cutaneous HPV infection (Astori et al., 199$; Tieben et al., 1993; Surentheran et al.,
199$; Meyer et al., 2000; Harwood et al., 1999; Forsiund et aL, 1999; Pfister et al., 2003;
Harwood et al., 2004; Shamanin et al., 1996; Boxman et al., 2000; de Villiers et al.,
1997). Malysis of cloned amplicons generated with FAP identified more types per
sample than direct PCR-sequencing. However, BPV DNA was identified repeatedly in
several instances, especially with HVP2/B5 primers, by direct sequencing of amplicons
while only HPV-unrelated sequences could be cloned and sequenced from these
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specimens. Studies relying solely on PCR-sequencing aller cloning for typing HPV
sequences on the skin could thus have underestimated the prevalence ofHPV infection.
The detection rate and spectrum of cutaneous HPV infection in healthy
individuals and individuals with cancerous lesions of the skin was described here for the
first rime in Canadians. In agreement with other studies, we found a great diversity of
HPV types on the skin, identifying 77 types or putative types in 75 samples (Surentheran
et al., 199$; Antonsson et al., 2003; Shamanin et al., 1996; Shamanin et al., 1994;
Harwood et al., 2004). Overali, types belonging to Beta-papillomavirus genus species 1
and 2 predominated in our population. Because FAP primers were used in our study, the
prevalence of type 3$ and candidate type 92 may have been underestimated (Forsiund et
ai, 2003). Several of the cutaneous types undetected with FAP 59/64 (Harwood et al.,
1999; Forslund et al., 1999) could be detected with HVP2/B5. A more complete
evaluation of HPV type-specific prevalence could have been done by using nested
primers with HVP2IB5 (Harwood et al., 1999; Harwood et al., 2004) or by adding
another degenerate primer pair for EV types (Astori et al., 199$; Meyer et al., 2000). In
our study, one of the putative HPV types was related to HPV-22 in the species Beta 2.
The other two novel types shared homology with putative new types detected on the skin
as mentioned in the table and were also related to known types HPV-47 for L102 (species
Beta 1) and HPV-15 (species Beta 2) for L103. These latter species of Beta
papillomavirus contain several ofthe Epidennodyspiasia verruciformis (EV)-related IIPV
types. In other reports, novel types ftequently shared sequence homology with EV and
cutaneous types (Forsiund et al., 1999; Harwood et al., 1999; Astori et al., 199$;
Harwood et al., 2000).
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In our study, over 80% of healthy controls irrespective of age were infected by
HPV, with sometimes up to eleven types per sample. IIPV is ubiquitous in humans even
without lesions (Forsiund et al., 1999; Fawe et aL. 199$; Antonsson et al., 2003;
Antonsson et al., 2000; Weissenbom et al., 1999; Astori et al., 199$; Boxman et al.,
1999; Boxman et al., O AD; de Villiers et al., 1997; Wieland et aL. 2000). HPV sequences
can be found in 63% to $0% of skin swabs from healthy individuals (Forsiund et al.,
1999; Antonsson et al., 2000; Antonsson et al., 2003). Nearly haif (46.8%) of samples
from individuals without skin lesion contained more than one type in our study, similar to
other studies on healthy individuals (Antonsson et al., 2000; Antonsson et al., 2003;
Forsiund et al., 1999). HPV types identified in skin swab samples depend on the site
sampled on the body, the site most frequently positive being the forehead (Forsiund et al.,
1999; Antonsson et al., 2000). The same HPV type(s) is usually detected in multiple
biopsies of tumours or normal skin obtained from the same individual, indicating a
widespread colonisation by HPV types (Mtori et al., 199$; De Jong-Tieben et al., 1995).
Types detected in perilesional swab samples from AK were different from those
in SCC. Two studies also reported that the spectrum of I{PV types detected in SCC and
AK was also different (Pfister et ai, 2003; Forslund et al., 2003). These resuits suggest
that HPV may play at most the role of cofactor to other carcinogens implicated
throughout carcinogenesis to invasive cancer. Beta-papillomavirus species 1 and 2 were
associated with AK in our work as reported previously (Harwood et al., 2000; Pfister et
al., 2003; Boxman et al., O AD). Participants with SCC were mainly infected with novel
putative types in contrast with previous reports reporting the predominance of EV types
(Harwood et al., 2000; de Villiers et al., 1997; De Jong-Tieben et al., 1995; Harwood et
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al., 2004). Perilesional swab samples from individuals with AK or SCC contained a
greater number of types than swab samples ftom healthy controls. Perilesional swabs
have been shown to contain a greater number of types than biopsy of lesion (Forsiund et
al., 2003). HPV types detected in biopsies of skin tumours are usually fourni in the
perilesional skin swab sample (Forsiund et al., 1999). Perilesional swab samples are more
ofien positive and contain more HPV types than biopsies. This could explain our higher
rate ofNPV infection in individuals with skin lesions compared to studies testing biopsy
samples.
Putative novel types FA5 1 and FA62 were ftequently detected in individuals with
precancerous or cancerous skin lesions. HPV fA5 1 has been reported in two patients
with basal celi skin carcinoma and AK (Forsiund et al., 2003; forsiund et al., 2003) and
infrequently in healthy individuals (Antonsson et al., 2003). The association between
HPV infection and AK or SCC in our work should be investigated in a larger case-control
study with enhanced power and a more systematic approach to accming subj ects so as to
minimise potential biases. Such a study should include a more thorough evaluation of
other factors associated with SCC such as exposure to IJV light. Some have reported that
HPV detection was increased in normal individuals at sun-exposed areas (Antonsson et
al., 2000; Kiviat, 1999; de Villiers et al., 1999).
Renal transplant recipients were ah infected by HPV as reported in a recent study
(Forslund et al., 2003). The smahl number of participants with renal allografi precluded
establishing differences in prevalence of HPV with non-immunosuppressed individuals.
Several studies have demonstrated that immunosuppressed patients have a higher
prevalence of cutaneous HPV infection (Forslund et al., 2003; Harwood et al., 2000;
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Antonsson et al., 2000; Boxman et al., 1999). Despite the small number of participants,
our study suggests that immunosuppressed individuals are infected with a greater number
of types per sample than immunocompetent individuals ofthe same age group. One study
had already reported that immunosuppressed individuals had more coimnonly multiple
type infections (Harwood et al., 2000). HPV putative novel type FA23 was detected more
ftequently in renal transplant recipients than healthy individuals. This putative type had
been described initially in renal transplant recipients and patients undergoing dïalysis
(Antonsson et ai, 2000). It has also been detected in several countries in normal
individuals (Forsiund et al., 2003; Antonsson et al., 2003).
This study demonstrates that the ubiquity and type-diversity of cutaneous HPV
infection reported in several populations are also present in our setting. It is possible that
the HPV types involved in SCC are distantly related to actual known types and have not
yet been described. This could explain the difficulty in obtaining concordant resuits on
the role ofIIPV in skin cancer across studies. The fact that swabs from individuals with
SCC contained only novel types in our population supports the concept that the types
associated with these lesions have yet to be discovered. Our study supports an association
between Beta-papillomavims genus with AK. Prospective studies are needed to
determine whether or flot the role of certain HPV types is directly causal or as a cofactor
to stronger carcinogens sucli as UV light. Studies of different populations at high-risk
using several primer pairs and low-stringency PCR investigations could reveal types
more strongly associated with these lesions. Large-scale epidemiological studies need to
be conducted to better investigate the associations with Beta-papillomavirus and SCC as
well as the potential role of novel types.
$0
Table 1. HPV detection rates in swab samples from renal transplant recipients,
individuals with various cutaneous lesions and healthy controls.
Skin lesion No. of patients No. of (%) of samples positive for HPV sequences
PCR FAP59/64 PCR HVP2/B5 Total
Healthy controls <50 yrs 34 30 ($8) 4 (12) 30 (88)
Healffiy confrols 50 yrs 13 11 ($5) 0 (0) 11 (85)
Renal transplant recipients 8 8 (100) 1 (13) $ (100)
Actinic keratosis 12 12 (100) 2 (17) 12 (100)
Squamous ceil carcinoma $ 7 (88) 2 (25) 7 (8$)
Ail participants 75 68 (91) 9 (12) 6$ (91)
Skin samples were amplified blindly in parallel with FAP 59/64 and HVP2IB5 primer
pairs as described in the methods section. Six samples tested negative for f3-globin: 2
from healthy controls, 1 from an individual with AK and 3 from individuals with SCC
carcinoma. Statistical significance for each comparison between FAP59/64 and HVP2/B5
was p<O.001 except for individuals with 5CC for whom a p=O.O4 was obtained.
Table 2. Detection rates ofHPV types in 75 3-g1obin-positive swab samples.
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NPV Type No. of samples positive by % agreement (95% Cl) Kappa (95%)
Boffi cloning only Direct only
FAP59/64
Ail types’ 50 112 15 97.8 (97.4-98.0) 0.82 (0.69-0.94)
Frequent types2 30 59 $ 87.9 (84.9-90.0) 0.92 (0.79-1.00)
Rare types3 20 53 97.8 (96.9-98.5) 0.85 (0.72-0.97)
5 0 3 0 96.0(88.5-99.1) lIC
8 2 2 1 97.3 (90.3-99.0) 0.55 (0.33-075)
12 2 2 2 947 (86.7-98.3) 0.47 (0.25-0.70)
17 0 3 0 96.0(88.5-99.1) nc
25 2 1 0 98.7 (92.2-99.9) 0.79 (0.57-1.00)
38 2 2 0 97.3 (90.3-99.0) 0.65 (0.44-0.87)
49 3 4 0 94.7 (86.7-98.3) 0.58 (0.37-0.78)
$0 1 2 2 94.7 (86.7-98.3) 0.31 (0.07-053)
FA2 0 3 0 96.0 (88.5-99.1) Nc
FA7 1 2 97.3 (90.3-99.0) 0.49 (0.30-0.68)
fA14 0 5 0 93.3 (85.0-97.5) Nc
FA16 2 4 0 94.7 (86.7-98.3) 0.4$ (0.29.067)
FA21 0 2 97.3 (90.3-99.0) nc
FA23 2 1 0 98.7 (92.2-99.9) 0.79 (0.57-1.00)
FA35 0 3 0 97.3 (90.3-99.0) nc
FA51 2 3 2 93.3 (85.0-97.5) 0.41 (0.19-0.63)
FA62 2 2 0 97.3 (90.3-99.0) 0.65 (0.44-0.87)
FA75 1 2 97.3 (90.3-99.0) 0.49 (0.30-06$)
FAY12 0 3 0 96.0 (88.5-99. 1) ne
FA118 1 3 0 96.0(88.5-99.1) 0.39(0.21-0.57)
FA127 2 2 0 97.3 (90.3-99.0) 0.65 (0.44-0.87)
LIOl 1 4 0 947 (86.7-98.3) 0.32 (0.15-0.48)
BVP2/B5
Mitypes5 2 3 6 9$.$(97.6-99.5) 0.31(0.28-0.33)
17 1 0 100 (94.2-100.0) 1.00 (0.77-1.00)
25 1 0 1 98.7 (92.2-99.9) 0.66 (0.45-0.87)
49 0 1 0 98.7 (92.2-99.9) ne
FA51 0 1 2 (92.2-99.9) ne
fA119 0 1 98.7 (92.2-99.9) ne
FA23 0 0 1 98.7 (92.2-99.9) ne
fA112 0 0 1 98.7(92.2-99.9) ne
VS92.1 0 0 1 98.7 (92.2-99.9) Ne
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The detection rates of HPV types in 75 3-g1obin-positive swab samples was assessed by
direct sequencing of amplicons or by sequencing of cloned amplicons generated with
fAP59/64 and HVP2IB5 primers as described in the methods section. Only types
identified in >2 samples with FAP59164 and ail types identified with HVP2/B5 are shown
in the table. 1: AIl typing resuits for 77 genotypes in 75 samples (5775 typing resuits). 2:
selecting only types (n=24 types) detected in >2 sampies (n=23 sampies) for 552 typing
results. 3: Seiecting only types (n=53 types) detected in 2 samples (n=52 samples) for
2756 typing resuits. 4; nc is for flot calculated. 5: ail typing resuits for 8 genotypes in 75
samples (for a total of 600 typing resuits to be compared).
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Table 3. New putative types and the closest related known HPV types
No. of participant Putative new HPV Closest related type % homoLogy Fragment size (nt)
5 LIOl 22 88% 483
1 L102 fA121 81% 430
1 L103 FA57 83% 181
Sequences of putative new types.
Putative new type LIOl,
CGGCCGCGAATTCGCCCTTCCTATATCTCTCATGTCGCCATCCTCTATAACACTATTTTT
TAACTCTAGTGGAGGACATAGCCCTCCTGACTGCCTGCATCTTCACACACTGGTGCTTT
ATCCcATGTTCCCCTAAACAAGGTATGCAACCAATAATAZ-ACATTTGTACCTGTTTAGG
ATCAAAAGAAACATTTCTTCTATCATCTGCTGTGCCTGTCTGGCGTTCACTAGGATTTTC
AGTGTCATGTAATTTATTAÎATAATGGATGACCTGTGGTACCTACACCTATGGGCTGTCC
TCTCCCGATTTCTGCCTTTGCGCCCATACTAATCTGTACCTCTCAGGATCATGT
TGTCATATCTGCTAGAGCAAATTTATTAGGATCTGGAAAGGTTACTCTAAATGCTCTATA
CTGGTTCCCTGACACCTTTGGGACTTCTATTTTTGCTCCATCTGTTGCTGATCTTACATC
AAAATAAGGATGCCCCACAGTTAA.AGGGCGAATTCGTTTAICCTGCAGGACTAG
Putative new type L102,
GCGGCCTTCCCTATCAAGAAAAACGCCATCTTGTATATTCTATTTACTAACTGAATTGG
TGGGCAATCACCCTTTCTAACTTGTACTCCTTCACAAGGTTTTGCTACATCCCAATGTTC
ACCAATTGGTGGAGCACAACCTACAATAAATAGCTGAGTTTGTTTAGGGTCAAAAGATAC
ATCCTGACGATTATCATCACTTTGTTTAATATATTTGTTAGGGTTTTCTGTATCACCTAG
TTTGTTATATAAAGGATGTCCAGTAGTACCTATTCCTAAAGGACCGCCTCTACCAACTTC
CAATCCTCT2AGTTTCCATACTAATCTTTGGTGTTCTGGATTATAACACCTTTCTCAATT
AAGGCAAGCGATTAGGATCTGGTAATTTCATACGA1ACTCTACTGACTTCCTGAG
ACATGAGGAACTAATATTTTAGTTCTATCTTGAACATCCCGAATAGGAAAATATGGATGC
CCCACAGTTAAAGGGCCGATTCGCGGCCGCTTAAATTCAATTCGCCCCTATAGTGAGTC
GTATTACAAAT
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Putative new type L103,
TATCTGACATGTCGCCATCCTCTATATATGAATTAACTATTCTAAGGAGGGCATC
ACCATTCTTTACTTCTGTGGTAGCACAGGCCTTTGCAGCATCCCAATAGGCACCAGTACA
AGGTTCACAACCCACAATTAPITAATTGGGTCTGTTTTGGGACCATGGACACATTTTGTCT
ATTATCAGTGCTGCTAGTAAAATATTGATTAGGATTTTCAGTGTCATTTAATTTATTTAG
TAAAGGATGACCTGTAGATCCTATGCCCAATGGGCCACCTCTCATTATTTCTATGCCTCT
TAGTTTCCATACTAGTCTTTCTGTATCAGGGTCATATATAGTGGGATCTACTAAAGCAAA
TCTATTAGGGTCAGGCAAGTAGTCTAAACACTCTATATTGATTTCCTGACACTTTTGG
TACAAGTTCGTTTCCAGTTGGATCTTTTACAGGATAGGATGCCCCACAGTTAAAGG
GCGAZTTCGCGGCCGCTAAATT
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Table 4. Detection rates ofHPV types in 75 f3-globin-positive skin samples selecting
IIPV types detected in more than two samples.
Type No. of positive samples (%)
Normal <5Oyrs Normal >SOyrs Normal AK 8CC Allograft(n=34) (n=13) (n=47) (n=12) (n=8) (n=$)
5 1(2.9) 0(0) 1(2.1) 2 (16.6) 0(0) 0 (0)
$ 1(2.9) 1(7.7) 2 (4.3) 2 (16.6) 0 (0) 1(12.5)
12 2 (5.9) 2 (15.4) 4 (8.5) 0 (0) 0 (0) 1 (12.5)
17 1 (2.9) 1 (7.7) 2 (4.3) 1 (8.3) 0 (0) 0 (0)
25 1(2.9) 0(0) 1(2.1) 2 (16.6) 0(0) 0(0)
3$ 3 ($.$) 0 (0) 3 (6.4) 1 ($.3) 0 (0) 0 (0)
49 5 (14.7) 1(7.7) 6 (12.8) 1(8.3) 0 (0) 0 (0)
$0 1(2.9) 1(7.7) 2 (4.3) 1(8.3) 1(12.5) 0 (0)
fA2 1 (2.9) 1 (7.7) 2 (4.3) 1 (8.3) 0 (0) 0 (0)
FA7 0(0) 1(7.7) 1(2.1) 1(8.3) 0 (0) 1(12.5)
FA14 1(2.9) 1(7.7) 2 (4.3) 1(8.3) 1(12.5) 1(12.5)
FAY6 1(2.9) 3 (23.1) 4 ($.5) 1(8.3) 0 (0) 1(12.5)
FA18 1 (2.9) 2 (15.4) 3 (6.4) 0 (0) 0 (0) 0 (0)
FA23 1(2.9) 0 (0) 1(2.1) 0 (0) 0 (0) 2 (25)
FA35 2 (5.9) 1 (7.7) 3 (6.4) 0 (0) 0 (0) 0 (0)
FA51 1(2.9) 0 (0) 1(2.1) 3 (25) 3 (37.5) 0(0)
FA62 0 (0) 1(7.7) 1(2.1) 0 (0) 3 (37.5) 0 (0)
FA75 0(0) 1(7.7) 1(2.1) 1(8.3) 0(0) 1(12.5)
FA85 2(5.9) 0(0) 2(4.3) 1(8.3) 0(0) 0(0)
fA112 0(0) 2(15.4) 2(4.3) 0(0) 1(12.5) 0(0)
FA11$ 2 (5.9) 0 (0) 2 (4.3) 1(8.3) 0 (0) 1(12.5)
FAY19 1(2.9) 0 (0) 1(2.1) 0 (0) 1(12.5) 1(12.5)
FA127 0(0) 3(23.1) 3(6.4) 1(8.3) 0(0) 0(0)
LIOl 3 ($.$) 1 (7.7) 4 (8.5) 1 (8.3) 0 (0) 0 (0)
Bela 1-2 11(32.4) 4 (30.8) 15 (3 1.9) 11(91.7) 1(12.5) 4 (50)
Bela 3 5 (14.7) 1(7.7) 6 (12.8) 1(8.3) 0 (0) 0 (0)
Bela 5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (12.5)
Alpha2 1(2.9) 0(0) 1(2.1) 1(8.3) 0(0) 0(0)
Gamma 1(2.9) 2 (15.4) 3 (6.4) 0 (0) 0 (0) 1 (12.5)
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Resuits obtained with FAP and HVP2 primer pairs with direct sequencing or afier
cloning were combined for this table. HPV types 3, 15, 20, 24, 47, 94, 96, 19 , FA12,
FA13, FA15, FA2O, FA22, fA39, fA41, FA43, FA46, fA4$, FA56, L103, FA61,
FA64, FA65, FA67, FA70, fA74, FA1O8, FA1O9, FA114, FA12O, L102, FA121, FA13$,
FA139, RTRX7, FA12, FA32, were detected in only one sample while types 4, 23, 50,
93, FA1, FA21, FA25, FA26, FA27, FA28, FA37, FA45, FA53, fA83, FA90, FA91,
fA9$, VS92. 1, were detected in two samples each.
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Table 5. Burden ofHPV infection in 75 f3-globin-positive skin samples measured as the
number of types detected per sample ami underlying disease.
Disease No. of participants Median Range Mean (95% CI)
Normal<50 yrs 34 1.0 0-5 1.9±1.5 (1.4-2.4)
Normal 50 yrs 13 1.0 0-11 2.2±2.8 (0.5-3.9)
Normal 47 1.0 0-11 2.0±1.9(1.4-2.5)
AK 12 3.0 1-6 2.8±1.4(1.9-3.7)
SCC 8 2.0 0-5 2.3±1.7 (0.9-3.6)
AK+ SCC 20 2.5 0-6 2.6±1.5 (1.9-3.3)
Allograft recipient 8 3.5 1-7 3.6±2.1 (1.9-5.4)
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DISCUSSION
9$
0f the approximately more than 100 different types of human papillomavirus
identified hitherto, 40 are known to infect the genital tract, and some have been identified
as the causative agent of cervical cancer [2811. Over 20 HPV types have been identified
in patients with epidermodyspiasia verruciformis (EV), though only a few ofthese types,
mainly HPV-5 and 8, have been found to be associated with skin cancer [269]. Most of
the HPV types infecting the skin have yet to be characterized [1,241,270]. PCR with
primers chosen in conserved sequences in the Li and El open reading frames (ORF),
have been successflully used for the detection of a wide range of genital HPV types
[249,250,251,252]. The same strategies have been applied for the detection of cutaneous
types in epidemiological studies.
6.1.10 FAP 59164 primer pair:
PCR with universal primers specially designed for cutaneous HPV types has been
developed [2,225,228,238,248,253]. However, methods for the detection of cutaneous
HPV types have disadvantages such as nested PCR or combinations of several degenerate
primers. Forslund et al. designed a single pair of degenerate PCR primers FAP59/64
primarily aimed at the amplification of cutaneous HPV types. Two regions with a
relatively hîgh degree of nucleotide homology were found in the 5’end of the Li ORF.
The positions of the primers corresponded to nucleotides 5981-6001 and 6452-6436 of
the HPV-$ genome, yielding an amplicon of 47$ bp [241].
Studies using this primer pair showed high sensitivity, the assay being optimized
to allow the detection of less than 10 HPV DNA copies per test [2411. In that study, HPV
DNA was detected in 50% of all skin samples while in another study the detection rate
was 85% [236]. In our study, we were able to detect HPV DNA in 91% of ah B-globin
positive skin samples. This primer pair was also found to detect significantly greater
numbers of HPV-positive skin samples as compared to HVP2/B5 primer pair. In one
study where the investigators used FAP primers, 30 new types were identified that we
detected also in our study [1]. We could also detect three new types and revealed the
presence of 77 different types (22 known types, 55 putative novel types) in 75 samples.
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IIVP2IB5 primer pair:
The degenerate primer pair HVP2/B5 was described by Shamanin et alto detect
HPV from all groups with the exception ofthe phylogenetic clade comprising HPV-4, 48,
50, 60. Generally, the copy number detected byHVP2/B5 was high 5-5x104 copies which
is likely to be a consequence of the high degree of degeneracy of these primers
[228,253,2541.
HVP2/B5 primer pair detected ah cloned HPV types in one study and in up to
100% ofwart lesions in opposite to primers designed specifically for EV types, with the
exception of types 4, 48, 50, 60 and 65 [254]. The original degenerate primer pair
included primer C instead of primer B5. To improve sensitivity of the assay, less
degenerate primers were derived from the original degenerate HVP2/C pair. B5 was the
most efficient of these less degenerate primers [238]. In one study, HVP2IB5 proved to
be the most sensitive primer pair to detect the presence ofHPV DNA in skin samples but
was unable to detect HPV DNA in SCC [254] while CP62-69 detected the presence of
HPV DNA mainly in SCC and could not detect HPV DNA in warts and vulvar cancer
[2541.
In our study, HVP2/B5 primer was less sensitive than FAP59/64 primer. 0f the
47 swab samples from healthy individuals without skin lesion irrespective of age, 4 (9%)
contained HPV DNA with HVP2IB5 primers. Another study that used HVP2/B5 reported
a detection rate of HPV DNA of 75% in wart samples while it was 0% SCC samples
[254]. We could detect NPV DNA in 25% and 17% of 5CC and AK samples,
respectively. PCR-sequencing of amphicons generated with HVP2/B5 primers identified $
types (3 known types, 5 putative novel types) in the same set of samples.
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Comparison between fAP59/64 primer pairs versus IIVP2/B5
primer pair:
Until recently, it lias been technically difficuit to detect the HPV types involved in
skin cancer compared to genital HPVs, considerably hindering research in this area. In
early studies, detection of HPV DNA varied both in overail prevalence and in the
spectrum of HPV types detected [2131. As a consequence, the true prevalence of HPV in
cutaneous lesions was unknown. A limited number of studies have demonstrated
differences between efficiency of degenerate primer pairs to detect cutaneous HPV types
[256,266,279]. Degenerate primers AM were found to be more sensitive that degenerate
primers HD in one study [237]. HVP2IB5 primers had flot been compared with the most
efficient primers for detection of cutaneous HPV types, the FAP59/64 primers. Our
evaluation revealed that FAP59164 detected a greater number of cutaneous HPV infection
as well as more types per sample in healthy controls and individuals with various skin
lesions. Amplification efficiency may have been better with FAP59/64 primers because
they amplified a smaÏler DNA fragment (47$ bp versus 650 bp). Both degenerate primer
pairs amplify the 5’ end of the Li open reading frame, the most conserved gene within
the papillomavirus genome [110]. The fragment generated with FAP primers (nucleotide
positions 5981 to 645$ ofHPV-8) is nested within the amplicon generated with HVP2/B5
(nucleotide positions 5835-6481 ofHPV-8) [238,241]. Both primer sets have been shown
to amplify a broad spectrum of types, including novel RPV types [238,241]. FAP59/64
reaches excellent sensitivity endpoints for several cutaneous types down to 1-10 copies
per test maybe because of higher primers, length of the amplicons and due to cycling
parameter [241]. HVP2/B5 and FAP59164 have been utilized in several epidemiologic
studies [1,34,212,238,241,254,270,277,278]. The sensitivity of FAP59/64 and HVP2/B5
primers can be increased using nested PCR [256,285], a strategy that was not used in this
evaluation. Several studies have demonstrated that combined primer panels allow for a
more comprehensive evaluation of cutaneous HPV infection
[2,237,238,241,254,279,280,284,285J. In our study, even if FAP59/64 detected more
types than HVP2/B5, the combination ofresuits obtained with both primer pairs reported
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a greater number of positive samples. As found in this study, types identified by two
assays applied on the same samples can sometimes be different [237,238,254]. Using
only one degenerate primer pair will likely underestimate HPV prevalence on the skin.
Comparison between direct sequencing and sequencing after
cloning:
Cloning of amplicons has revealed additional HPV types ofien matching the type
detected with direct PCR-sequencing. Infections with more than 2 types were identified
in 62% of samples. HPV DNA sequences amplified by FAP were identified in 88% of
samples using sequencing of cloned amplicons compared to $0% by direct sequencing of
amplicons. The same sequence was detected by direct sequencing and sequencing of
cloned fAP amplicons for 42% of samples. HPV DNA was detected by HVP2/B5 in 5%
of samples by sequencing of cloned products compared to 12% by direct sequencing.
With HVP2IB5, the same type was identified in 22% of samples with both sequencing
procedures.
It is possible that sequencing many more clones might have detected additional
HPV types. We could have sequenced systematically 25 clones for all samples. Budget
and time restriction did flot allow to pursue this strategy. The yield would have been
minimal for samples with only 1-2 types per 5 to 10 clones. Sequencing ofcloned PCR
products sometimes revealed different types than direct sequencing. More types were
identified afler cloning which makes the cloning of PCR product necessary for a
complete evaluation of mixed I{PV type infections (Figure 11).
The agreement between PCR-sequencing of amplïcons directly and afler cloning
was also investigated in this study. Analysis of cloned amplicons generated with FAP
identified more types per sample than direct PCR-sequencing. However, especially with
HVP2IB5 primers, HPV DNA was identified repeatedly in several instances with direct
sequencing but only human sequences could be cloned and sequenced from these
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specimens. PCR-sequencing afier cloning thus did flot reveal any HPV infection in these
samples. Studies relying solely on PCR-sequencing afler cloning of amplicons for
detection and typing of HPV sequences on the skin could thus have underestimated the
prevalence of HPV infection. Ouf study not only supports combining resuits obtained
with different primer pairs but also with different sequencing strategies.
A
200 210 220 230
AN G AGG N UN C GAC T À C T C U TC C T C N N T T T TA T AAG À T N G AT G
B
190 200 210 220 230
A G G T ACA G AT T A G T AT o C T T G C AA A G G C T TAG ÀA ATC G G G AU A
190 ZOO 210 220 230
A A À T AT T T T G T C T A T C A T C T T A G À G G A G T T C C T A T A T U T À T T A C
C
Figure (11): Mixed HPV types are detected with fAP primers. The electropherograms in
panels A to C were from skin swab of normal person age above 50 years. (A) the sequence
was obtained by direct sequence shows features suggestive of the presence of at least more
than one distinct HPV types.(B) and (C) the sequence was obtained afier cloning appears to
be a single type in each colony different than other colonies.
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Clinical assessment of the skin samples:
Methods of collecting samples:
For most of the studies on cutaneous HPV infection, biopsies of the skin were
analyzed. A biopsy is the process of removing a portion of skin for diagnostic
examination. This invasive method increases the risk of infection because the skin barrier
has been broken and sutures are sometimes needed according to depth of the biopsy.
Simple methods for collecting skin celis include using wetted coffon-tipped swabs that
are drawn back and forward 4-5 times over an area of the skin and immersed in a tube
containing 500m1 of Preservcyt. Swabbing of the skin by using this simple method lias
been successfiuly used for detection of cutaneous HPV infection [1,241,270]. Perilesional
swab samples are more ofien positive and contain more HPV types than lesion biopsies,
explaining our higlier rate ofHPV infection in individuals with skin lesions compared to
studies testing biopsy samples that obtained HPV detection rates from 22% to 84% in
immunocompetent individuals [212,238,254,260,271,278,2821. Skin swabbing had been
utilised previously to estimate the rate of cutaneous HPV infection in the
immunocompetent host. Studies showed that 63%-80% of swabs from healthy
individuals or individuals with skin lesions contained NPV sequences [1,2411. Types
detected varied according to the site sampled on the body and varied over time, the site
most ftequently positive being the forehead [1,24 1]. 0f a total of 160 participants, the
prevalence of NPV in skin samples from renal transplant recipients, patients undergoing
dialysis and healtliy controls was 51% when the lefi arm was swabbed, 51% from the
right arm, 49% from the lefi thigh, 49% from the right thigh, and 80% ftom the forehead
[1]. HPV types detected in tumours were also frequently found in skin swab samples
[241]. Forehead skin samples contained less ftequently I{PV EV types than when
plucked eyebrow hairs were tested [242]. Other investigators have used invasive samples,
such as plucked hairs [242,248J and skin biopsy specimens [226,237,239,243], but they
obtained lower rates of detection ofHPV than ours.
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In our evaluation, epithelial ceils were collected with pre-wefted swabs and were
resuspended in Preservcyt. This is the first study to use Presewcyt to preserve the
integrity of DNA between collection and processing of samples for the detection of
cutaneous HPVs. A majority of samples tested positive for human DNA indicating the
excellent quality of samples. The high prevalence of}IPV DNA infection even in healthy
controls also supports the high quality ofthe DNA analysed.
Ubiquity of IIPV infection of the skin:
The detection rate and spectrum of cutaneous HPV infection in healthy
individuals and individuals with cancerous lesions ofthe skin was also described here for
the flrst time in Canadians. HPV can be detected on normal uninvolved skin and plucked
hair samples, includïng EV-related types, and is widely spread in humans without lesion
[1,237,241,259,270,273,274,276]. HPV DNA sequences have been detected in 35% to
63% of individuals with normal skin biopsies, supporting the concept that cutaneous
infection by HPV occurs frequently [2,237,241,287]. Such a high prevalence rate
complicates the investigation of association between HPV infection and NMSC [254].
Commensal infection by HPV on the skin has a worldwide distribution [2701. In our
study, over 80% of healthy controls irrespective of age were infected by HPV, with
sometimes up to 11 types per sample. In a recent international study, from 42% to 70% of
participants without skin lesion in different countries were infected by HPV on the skin
[270]. The prevalence of HPV DNA in samples of healthy skin from Bangladesh was
68%, Japan 54%, Ethiopia 52%, Zambia 42% and Sweden 70% [270]. In fact, in that
study up to 62% of samples was negative for human DNA sequences [270]. Our higher
rate could 5e explained by the use of Preservcyt to maintain the integrity of cellular
DNA, the use of a greater quantity of Taq DNA polymerase for amplification and
possibly by the population studied. Northern countries evaluated in that work had a 70%
prevalence rate of HPV infection, a rate near that found in our study. Our study shows
that the previously reported high prevalence and type diversity of skin papillomavims in
healthy also applies to individuals living in Canada [1,2,237,241,270,287]. These
findings emphasize the ubiquity and impressive diversity of genotypes amongst the skin
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papillomaviruses, both in human [1,270] and in animais [282]. Adapted to their hosts
presumably over hundreds of millions of years, these viruses are the first viral skin
commensal to be described.
Multiple type infections on each sample:
More than one HPV type can be detected within an individuai skin lesion or in
exfoliated skin cells [225,23$]. As in our study, another group reported that nearly 40%
of skin samples collected with a pre-wetted swab contained more than one type [241].
We report here that FAP could detect significantly a greater number of HPV types per
sampie than IWP2/B5. Nearly haif (46.8%) of samples from individuals wïthout skin
lesion contained more than one type in our study, similarly to an international study on
healthy individuals in whicb 39% of samples were multiple type infections [270].
Another study also revealed the multiplicity of HPV infection in heaithy hosts without
skin lesion [1]. We found no difference in the number of types per sample between
younger and older participants, although the small number of individuals above 50 years
old limited the power of our analysis.
As demonstrated in other studies, we found a great diversity of infection by
cutaneous types demonstrated by the detection of 77 types or putative types in 75 f3-
globin-positive samples [238,259,270,280,285]. Three studies have reported the presence
of 88 different types from 142 sampies, 50 types ftom 33 samples and 45 types from 49-
HPV-positive samples, respectively [1,270,278]. The same HPV type(s) is usually
detected in multiple biopsies of tumours or normal skin obtained from the same
individual, indicating a widespread colonisation by HPV types [237,243].
Specific NPV types:
Putative novel HPV types predominated in perilesional swabs from individuals
with SCC. Because fAP primers were used in our study, the prevalence of hpv type 92
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may have been underestimated [278]. Several of the cutaneous types undetected with
fAP 59/64 such as types 1, 2, 10 and 41 [241,279], can be detected with HVP2IB5
primers. A more complete evaluation of NPV type-specific prevalence could have been
donc by using nested primers with HVP2/B5 [279,280] or by adding another degenerate
primer pair for EV types [237,283]. Putative novel types fA5 1 and FA62 were the most
frequent types detected in individuals with cancerous lesions. HPV FA5 1 was associated
with the presence of AK or SCC in our population. HPV fA5 1 has been reported in two
articles in two patients with basal ccli carcinoma of the skin and solar keratosis
[256,278]. These two putative types were also reported inftequently in healthy
individuals [2701. A recent study on AK lesions revealed that 80% of frozen biopsies in
contrast to 40% of fixed tissue specimens contained HPV DNA sequences [284]. As in
the latter study, types 5, 8, 25 and 38 were frequent known types identified in AK lesions.
Unfortunately, primers used in that study were different ftom FAP primers and targeted
another region of the HPV genome. It is thus impossible to know if they also detected
putative types fA5 1 and FA62 in their patients.
In our study, HPV-49 was found in 6 healthy controls whule HPV fA127 and
fA16 were detected more ftequcntly in older participants. In opposite to other studies,
the most frequent type was flot HPV-5 but HPV-49 [270]. HPV-5 is more frequently
found in patients with psoriasis and none of our participants was afflicted by this disease
[259].
Novel IIPV types:
Forsiund, Antonsson et al. in 1999 designed FÀP primers for the first time. They
were able to detect five known HPV types and 12 novel HPVs types from eight patients
[241]. The novel HPVs types were fAl-fA9, FA1 1-fA13 [241]. One year later, they
studied of 160 participants and were able to detect 20 known HPV and 30 novel HPV
types [1]. The novel I{PV types were FA14-FA43 [1]. Three years later by using samples
from four different countries, they were able to detect more HPVs types that had not been
detected before [270]. Mmost ail of the putatively novel HPV types they described it
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their studies were detected in our study, in addition to three novel HPV types flot
described before: LIOl, L102, and L103.
Most consensus PCR protocols have revealed the presence of novel types on the
skin. We need to beffer characterise nove! types in order to develop optimised HPV
detection assays [23$]. There are now 96 HPV genotypes that have been fully
characterised and several hundreds putative papillomavirus types have been partial!y
identified in the form of short DNA fragments [110]. HPV genotypes have been recently
c!assified into 5 genus, each further divided into 1 to 15 species [1101. HPV types
detected on the skin belong to the alpha-, beta,- gamma-, Mu- and Nu-papillomavims
genus [110]. In our study, one of the putative HPV types was related to HPV-22 in the
specie 2 of the Beta-papillomavirus genus. The other two nove! types shared homology
with putative novel types detected on the skin and were re!ated to type 47 for L102
(specie f of the Beta-papillomavirus genus) and to type 15 (specie 2 of the Beta
papi!!omavirus genus) for L103. These two species of Beta-papi!!omavims contain
severa! of the old EV-related types. In other reports, nove! types ftequently shared
sequence homo!ogy with EV and cutaneous types [212,237,241,279].
Cutaneous disease and HPV types:
Cutaneous warts and benign epithelial tumours induced by some cutaneous HFV
types (HPV-1, 2, 3, 4, 7, and others), occur frequently in up to 20% of the population.
The highest prevalence is measured in chiidren and adolescents at the ages of 11-16.
These !esions undergo spontaneous resolution within two to three years [2891.
Non-melanoma skin cancer represents the most frequent cancer occurring among
the Caucasian population world-wide [171,283]. Various attempts have been made to
detennine the factors involved in the etiology ofnonmelanoma carcinomas ofthe skin. It
is widely accepted that the UV component of solar radiation is a major environmental
cause [172]. To study the mechanism by which papi!lomavims infections may contribute
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to the etiology of NMSC in patients without EV, the HPV types associated with such
lesions have to be identified. Different groups of investigators have screened various
numbers of samples of non-melanoma carcinomas of the skin from immunosuppressed
and non-immunosuppressed populations for the presence of HPV DNA sequences. A
diverse spectmm of HPV types was reported [228,225,284-288]. No single HPV type
was specifically identified in $CC and AK and RTR in some studies [235,263], while
other studies showed specific HPV types associated with some cutaneous diseases like
SCC or AK. HPV-5 and $ are strongly associated with non-melanoma skin cancer in EV
patients while they are harmless for the general population [260]. HPV-20, 23, 38 were
predominant in another study being found in 73% of ail malignant lesions, in 35%ofsolar
keratosis and in 13% ofthe warts [2J.
In our study, HPV types belonging to Beta-papillomavims genus species 1 and 2
predominated. The latter types were previously designated as EV-types. Beta
papillomavirus species 1 and 2 were significantly associated with AK in our work as
reported previously [212,274,284]. Participants with SCC were mainly infected with
novel putative types in opposite to previous studies reporting a predominance of EV
types [2,2 12,243,280]. The associations between HPV infection and AK or $CC in our
work shouid be investigated in a larger case-control study to increase power of analysis
and include a more thorough evaluation of other factors associated with SCC sucli as
exposure to UV light. In our study, we did flot control for sampling at sun-exposed or
non-exposed sites. Some have reported that HPV detection was increased in normal hosts
at sun-exposed areas [1,275,282]. However, ail healthy controls were sampled at the
same sun-exposed site, the forehead. HPV prevalence in swab samples from individuals
with lesions has also been shown to be similar when obtained from sun-exposed or non
sun-exposed sites [278]. Another group reported in Poland that EV-types were less
frequently detected in SCC than in AK [284]. The spectrum of HPV types detected in
individuals with SCC and AK was also different in another study conducted in Australia
[278]. This could suggest that HPV could play a role as a cofactor in the early steps of
carcinogenesis. An anti-apoptotic E6 activity may serve to allow ceils with cellular
damage induced by UV to survive and facilitate the persistence of UV-induced genetic
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changes. Reduced apoptosis was demonstrated in ceils transfected by the HPV E6 gene of
some EV or cutaneous types [281]. The Bak protein is involved in signalling apoptosis in
the skin exposed to UVB and is up regulated in skin exposed to UVs [195]. In vivo, celis
exposed to UV light showed a marked increase in p53 ami Bak in ail celi layers with
many apoptotic ceils being present, while those containing HPV E6 did flot show an
increase in Bak levels [195]. F6 protein from cutaneous HPV types targeted and
abrogated Bak function by promoting its proteolytic cleavage both in vitro and in
regenerated epithelium [195]. IIPV-positive skin cancers have undetectable leveis of Bak
protein in contrast to fTPV-negative cancers that expressed Bak [195]. Perilesional swab
samples from individuals with AK or SCC contained a greater number of types than swab
samples from healthy controls or biopsy of lesion [278]. The current evaluation is the
first to compare the burden ofIIPV infection between healthy individuals and those with
skin lesions.
Renal transplant recipients and IIPV:
Renai transplantation has been performed for more than 35 years with a large
success. However, the survival of the graft is associated with the induction and the
maintenance of an immunosuppressive status which predisposes to the development of
multiple skin disorders. These disorders include warts, hyperkeratosis, keratoacanthomas,
and skin malignancies. Skin cancers are considered to be the most frequent tumours in
transplant patients, usually developing in sun-exposed areas [291]. The incidence of skin
cancer is increased in transplant recipients as compared to the general population and
varies according to the country studied. Thus, Harteveit et al. [290] found a cumulative
incidence of skin cancer of 10% and 40% at 10 and 20 years, respectively, after
transplantation. This incidence is higher in Australians (45% and 70% at 10 and 20 years,
respectively, after transplantation). This difference could be related to more intense sun
exposure in Australia.
Various artempts have been made to determine the factors involved in the
aetiology of nonmelanoma carcinomas of the skin. It is widely accepted that the UV
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component of solar radiation is a major environmental cause [1721. As described before,
this is reflected by the body site distribution of lesions. Papillomaviruses play a crucial
role in the deveiopment of certain malignant tumors [292]. This has been demonstrated
cleariy in the case ofgenitai tumors such as cervical carcinomas. Specific types ofIIPVs
(high-risk HPV) have been implicated in neoplastic transformation. The transforming
ffinction of the HPV E61E7 gene products depends on the prior modification and
functional elimination of ceilular tumor suppressor genes and their products [293].
Certain types of HPV have the potential to induce malignant and benign genitai tumors
[294]. The HPV types ftom supergroup B (HPV-5 and related HPV types originally
isoiated ftom EV patients) have cutaneous tropism but their possible role in the aetiology
of NMSC is flot clear. The DNA of cutaneous HPV types is found both in solar actinic
keratosis and NMSC, especially among immunosuppressed organ transplant recipients
[295,296,297].
Renal transplant recipients were ail infected by HPV as reported in a recent study
[278]. The small number of participants in our study with renai allografi preciuded
establishing differences in prevalence of NPV with non-immunosuppressed individuals.
Several studies have demonstrated that immunosuppressed patients have a higher
prevalence of cutaneous HPV infection [1,212,273,278]. Despite the small number of
participants, our study demonstrates clearly that immunosuppressed individuals are
infected with a greater number of types per sample than immunocompetent individuals of
the same age group. One study had afready reported that immunosuppressed individuais
had more commonly multiple type infections [212]. HPV putative novel type FA23 was
detected more frequently in renal transplant recipients than healthy individuals older than
50 years of age. This putative type had been described initiaiiy in renai transplant
recipients and dialysis patients [1]. It has also been detected in a study conducted in
Australia at equai ftequency in immunosuppressed and normal individuais [278]. HPV
FA23 has also been reported in samples from Japan in neariy 10% of healthy participants
without skin lesion and in Sweden [270].
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So far, the vast majority of studies on cutaneous HPV infection have used
sensitive PCR methods. Less sensitive methods, such as Southern blot, are only
inftequently positive [284], indicating very low amounts of viral genomes [23 9,3061. But
common skin warts appear to have higher amounts of viral genomes, since HPV DNA
(jredominantly HPV-1 and 2) is readily detectable by the Southem blot technique [307J.
A significant problem for investigations of the association between cutaneous
HPV and nonmelanoma skin cancer is that cutaneous HPV is part of the microbiological
fora of healthy human skin as shown in our study and other studies
[1,23 7,248,256,257,270,2781. The site of replication of cutaneous HPV DNA might be
stem cells of the hair follicle [242,248,2721 or of eccrine ducts [308]. These sites could
also be the origin for non-melanoma skin cancer [308,3091. However, it is not known
whether cutaneous HPV are involved in the development of skin cancers.
if viral particles are produced and shed from infected healthy skin, they are likely
to be contaminating large areas ofthe body surface, including the surface of skin tumors.
if so, punch biopsies of tumors might be scored as HPV positive by PCR, although the
viral DNA is not present throughout the tumor. Forslund, et al. [245], investigated
specffically whether the HPV DNA prevalence on the surface of skin tumors differed
from the prevalence in biopsies from the same tumors. The prevalence ofHPV DNA was
much higher (69%) in the perilesional swab samples than in biopsies taken afier removal
of superficial ceil layers by repeated tape stripping (12%) [245]. This result demonstrates
that cutaneous HPV DNA is commonly present over skin lesions but to a lesser extent
throughout the lesion. The fact that swab samples form healthy skin sites were found to
be HPV positive to about the same extent as swab samples from the tumors, suggests that
presence of virus is not specifically related to the tumor below
[1,237,248,256,257,270,278]. Whether the presence of viral DNA in superficial skin is
due to viral particles or to episomal HPV genomes of infected ceils is not known.
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Conclusion
This study demonstrates that the multiplicity and wide spectrum of cutaneous
HPV infection reported in several populations are also presents in Canadians, a
population at high-risk for $CC. It is possible that the HPV types involved in SCC are
distantly related to actual known types and have flot yet been described. This could
explain the difficulty in obtaining concordant resuits on the role of HPV in skin cancer
across studies. The fact that perilesional swabs ftom individuals with SCC contained only
novel types in our population supports the concept that the types involved in this
pathology have yet to be discovered. Our study supports an association between Beta
papillomavirus genus with AK. Prospective studies are needed to determine if this
relationship is one of causality and assess if HPV is central to SCC or is acting merely as
a cofactor to stronger carcinogens such as UV light. Normal skin is constantly repairing
UV-induced damage through normal DNA repair mechanisms but in case of SCC and
AK, HPV may play role of a cofactor and enhance transformation by a mechanism not
yet clear. Further evaluation on these mechanisms needs to be done. Studies on different
populations at high-risk using several primer pairs and low-stringency PCR investigations
could reveal types more strongly associated with these lesions. Large-scale
epidemiological studies need to be conducted to better investigate the associations with
Beta-papillomavirus and SCC as well as the potential role of novel types. Prospective
studies are also needed to define the natural history ofcutaneous HPV infection.
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